Pharmaceutical composition for treating or preventing at least one disease selected from group consisting of inflammatory bowel disease and intestinal tumor
Block DCIR signaling by blocking DCIR signaling by using dendritic cell immune receptor-double-stranded assialic acid N-type sugar chains, Clec4a2-/- mice are susceptible to autoimmune diseases and intestinal inflammatory tumors. The problem of this has achieved effective inhibition of inflammatory bowel disease and intestinal tumors.
Patent Information
- Application Number
- CN202380028559.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-21
- Filing Date
- 2023-01-23
- Publication Date
- 2024-11-01
AI Technical Summary
Clec4a2-/- mice are susceptible to autoimmune diseases such as collagen-induced arthritis and experimental autoimmune encephalomyelitis, and plays an important role in intestinal inflammation and tumor occurrence, but their specific mechanism of action is still Not clear.
Provided is a pharmaceutical composition containing a binding inhibitor or dendritic cell immune receptor inhibitor between dendritic cell immune receptors-double-stranded assialic acid N-type sugar chains for the treatment or prevention of inflammatory bowel disease and intestinal tumors, inhibit inflammation and tumor occurrence by blocking DCIR signals.
By inhibiting DCIR signal, it can effectively inhibit the occurrence of inflammatory bowel disease and intestinal tumors, improve the inflammatory condition of the intestinal tract, reduce the expression of inflammatory cytokines, and enhance the homeostasis of the intestinal tract.
Smart Images

Figure CN118891061A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to a pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors. Background Art
[0002] Inflammatory bowel disease (IBD), such as Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the intestine that eventually leads to the development of colon tumors. It is well known that innate immune receptors such as C-type lectin receptors (CLR) and Toll-like receptors (TLR) expressed in the intestine not only realize the host's defense against pathogens, but also recognize resident microorganisms and food components and induce reactive oxygen species (ROS), antimicrobial proteins (AMPs), cytokines, chemokines, etc., and play an important role in the pathogenesis of IBD. Thus, in order to maintain intestinal homeostasis, a perfect balance between the resident microbiota and the mucosal immune system is necessary.
[0003] Based on this background, the inventors found that Dectin-1, which is a CLR that recognizes β-glucan, previously induced the antimicrobial protein S100A8 in the intestine by recognizing β-glucan in food, thereby inhibiting the proliferation of Treg-inducing bacteria, Lactobacillusmurinus (L.murinus). Therefore, by blocking Dectin-1, the proliferation of L.murinus in the intestine is promoted, and Treg cells are increased, thereby inhibiting the onset of colitis. In addition, another CLR, MGL1, expressed on colorectal squamous epithelial (cLP) macrophages, binds to Streptococcus and Lactobacillus species to induce IL-10, thereby improving colitis caused by chemicals.
[0004] Dendritic cell immune receptor (DCIR; gene name Clec4a2) is another member of the CLR family, mainly expressed in natural immune cells of bone marrow origin such as dendritic cells (DC) and osteoclasts. DCIR is different from Dectin-1, which has a hemi-ITAM, and has an ITIM in the intracellular region, and negatively regulates multiple signal transduction pathways by recruiting protein tyrosine phosphatase SHP-1.
[0005] Previously, the inventors reported that aged Clec4a2- / - mice spontaneously develop autoimmune sialadenitis and enthesitis (see Non-Patent Documents 1 to 3).
[0006] Prior art literature
[0007] Non-patent literature 1: Fujikado N et al. Dcir deficiency causes development of autoimmune diseases in mice due to excess expansion of dendritic cells. Nat. Med. 14, 176-180 (2008).
[0008] Non-patent literature 2: Maruhashi T. et al. DCIR Maintains Bone Homeostasis by Regulating IFN-g Production in T Cells. J. Immunol. 194, 5681-5691 (2015).
[0009] Non-patent literature 3: Kaifu, T. et al., DCIR and its ligand asialo-biantennary N-glycan regulate DC function and osteoclastogenesis. J. Exp. Med., 218(12), e20210435(2021). Summary of the invention
[0010] Problem that the invention aims to solve
[0011] Clec4a2- / - mice are susceptible to autoimmune diseases such as collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE). In Clec4a2- / - mice, the DC population is expanded and the antigen presentation ability of DC is enhanced, indicating that this enhanced antigen presentation ability is the cause of the autoimmunity and excessive response to antigen stimulation in Clec4a2- / - mice. In addition, it was found that in the BMCs of Clec4a2- / - mice, granulocyte macrophage colony-stimulating factor (GM-CSF) promotes the differentiation of myeloid cells (BMCs) into DCs, leading to the hyperphosphorylation of the intracellular signal transduction molecule, signal transducer and activator of transcription 5 (Stat5). It is believed that DCIR controls the signal downstream of GM-CSF by recruiting the dephosphorylase SHP-1 on ITIM and inhibiting the phosphorylation of downstream Stat5. Furthermore, DCIR inhibits the production of inflammatory cytokines such as IL-1β and IL-23 from myeloid cells such as macrophages by inhibiting signals such as TLR4, 7, 8, and 9. The results showed that in DCIR-deficient mice, components such as LPS and DNAD in intestinal bacteria strongly induced the expression of IL-1β and IL-23, and therefore, these cytokines led to a very enhanced expression of GM-CSF. In this way, DCIR is also believed to be related to intestinal inflammation or anti-tumor immunity. On the other hand, it is not clear how DCIR is involved in the occurrence of intestinal inflammation and tumors.
[0012] In the above background, it is useful to clarify the role of DCIR in intestinal inflammation and tumors, so as to treat or prevent such diseases. The present disclosure provides a novel pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors.
[0013] Solutions to the problem
[0014] The solutions for solving the above problems include the following aspects.
[0015] <1> A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors, comprising: a dendritic cell immunoreceptor-double-stranded desialylated N-type sugar chain binding inhibitor or a dendritic cell immunoreceptor inhibitor, and a pharmaceutically acceptable carrier.
[0016] <2> The pharmaceutical composition according to <1>, wherein the dendritic cell immunoreceptor-double-stranded asialo N-type sugar chain binding inhibitor or the dendritic cell immunoreceptor inhibitor is an antibody.
[0017] <3> The pharmaceutical composition according to <1> or <2>, wherein the inhibitor of binding between dendritic cell immunoreceptor and double-stranded asialo N-type sugar chain is an anti-double-stranded asialo N-type sugar chain antibody.
[0018] <4> The pharmaceutical composition according to <1> or <2>, wherein the dendritic cell immunoreceptor-double-stranded asialo N-type sugar chain binding inhibitor or the dendritic cell immunoreceptor inhibitor is an anti-dendritic cell immunoreceptor antibody.
[0019] <5> The pharmaceutical composition according to <2>, wherein the antibody is a mouse antibody, a chimeric antibody, a humanized antibody, or a human antibody.
[0020] <6> The pharmaceutical composition according to <2>, wherein the antibody is a humanized antibody.
[0021] <7> The pharmaceutical composition according to <2>, wherein the antibody is a full-length antibody or a low-molecular-weight antibody selected from the group consisting of Fab, Fab', F(ab')2, scFv, and bispecific antibodies.
[0022] <8> The pharmaceutical composition according to any one of <1> to <7>, wherein the intestinal tumor includes at least one selected from the group consisting of colon cancer, rectal cancer, and small intestinal cancer.
[0023] <9> The pharmaceutical composition according to any one of <1> to <8>, wherein the inflammatory bowel disease includes at least one selected from the group consisting of Crohn's disease and ulcerative colitis.
[0024] Effects of the Invention
[0025] According to the present disclosure, a novel pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors is provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1A-1 ( Figure 1A-1 to Figure 1I ) is a graph showing that the expression of the Clec4a gene is locally enhanced in inflammatory bowel inflammation and that Clec4a2- / - mice show resistance to DSS-induced colitis regardless of the resident intestinal microbiota. Figure 1B The data in ∼D are representative of 4 independent experiments. Figure 1E Data in ~G are representative of 2 independent experiments. Figure 1B The data of A, C, E, and F are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. Figure 1A-1) Wild-type (WT) mice were given drinking water containing 4% dextran sulfate sodium (DSS) for 7 days, and then given normal drinking water for 5 days. Total RNA was extracted from the colon on day 12, and the expression intensity of Clec4a2 was determined by real-time PCR (n=5 / group).
[0027] Figure 1A-2 The data (GSE10616) on gene expression of human colitis in the GEO database of NCBI show the expression of human DCIR gene in the affected area in Crohn's disease (colonic type (C-CD); n=15, rectal type (IC-CD); n=18) and ulcerative colitis (UC, n=10) compared with healthy controls (HC, n=11).
[0028] Figure 1B is to Figure 1B to Figure 1D )WT and Clec4a2- / - mice were housed in different cages and given 4% DSS for 7 days, followed by normal water for 5 days (n=8 / group). Figure 1B ) Body weight was measured daily, and severity scores were assessed every 2 days.
[0029] Figure 1C On the 12th day after the start of DSS administration, the mice were euthanized, and the macroscopic pathology of the colon was confirmed and the length of the colon was measured.
[0030] Figure 1D Colon tissues were removed from mice euthanized on the 12th day after the start of DSS administration, and distal histological analysis was performed (H&E staining, 40×).
[0031] Figure 1E yes( Figure 1E ~I) After weaning, WT and Clec4a2- / - mice were cohabitated for 4 weeks, and then given 4% DSS for 7 days in the same cage, and then given normal water for 5 days (n=5 / group). Figure 1E ) Body weight was measured daily, and severity scores were assessed every 2 days.
[0032] Figure 1F On the 12th day after the start of DSS administration, the mice were euthanized, and the macroscopic pathology of the colon was confirmed and the length of the colon was measured.
[0033] Figure 1G On the 12th day after the start of DSS administration, the mice were euthanized, and the colitis sites were subjected to histological analysis (H&E staining, 40×).
[0034] Figure 1H Nucleic acid was extracted from the feces of mice before cohabitation, and the composition of representative bacterial species in the intestinal flora was determined by real-time PCR of 16S rRNA sequences (n=5 / group).
[0035] Fig. 1I After 4 weeks of cohabitation, nucleic acid was extracted from the feces of the mice, and the composition of representative bacterial species in the intestinal flora was determined by real-time PCR of 16S rRNA sequences (n=5 / group).
[0036] Figure 2A ( Figure 2A (F) is a graph showing that the infiltration of monocytes and neutrophils is reduced, but the infiltration of Treg cells is not reduced, in the colonic lamina propria (cLP) of Clec4a2- / - mice after induction of DSS-induced colitis. Figure 2A The data in Figure 4 are representative of three independent experiments. Figure 2E Data in A and F are representative of 2 independent experiments. Data are expressed as mean ± SD. **P < 0.01. Figure 2A 1, WT and Clec4a2- / mice were housed in different cages and euthanized on day 12 without DSS treatment (n=5 / group). CD45 expression of cLP was measured by flow cytometry. + The proportion of Ly6C+CD11b+ monocytes in the cells.
[0037] Figure 2B As shown in FIG1 , WT and Clec4a2- / - mice were housed separately and euthanized on day 12 without DSS treatment (n=5 / group), and the CD45 expression of cLP was measured by flow cytometry. + Ly6G in cells + CD11b + The proportion of neutrophils.
[0038] Figure 2C As shown in FIG1 , WT and Clec4a2- / - mice were housed separately and euthanized on the 12th day after DSS treatment (= 4 / group), and the CD45 expression of cLP was measured by flow cytometry. + Ly6C in cells + CD11b + The proportion of monocytes.
[0039] Figure 2D As shown in FIG1 , WT and Clec4a2- / - mice were housed separately and euthanized on the 12th day after DSS treatment (= 4 / group), and the CD45 expression of cLP was measured by flow cytometry. + Ly6G in cells + CD11b + The proportion of neutrophils.
[0040] Figure 2EAs shown in FIG1 , WT and Clec4a2- / - mice were housed separately and euthanized on the 12th day after DSS treatment (= 4 / group), and the CD45 expression of cLP was measured by flow cytometry. + CD4 in cells + and CD8 + T cells and CD4 + Foxp3 + The proportion of Treg cells.
[0041] Figure 2F On the 12th day after the start of DSS administration (n=4 / group), the colons were removed from these mice, and the expression levels of Foxp3, Tgfb, and Tbx21 genes were measured by real-time PCR.
[0042] Figure 3A ( Figure 3A (L) is a graph showing that the expression of inflammatory cytokines and chemokine genes such as Il17a and Cxcl2 was decreased in Clec4a2- / - mice after DSS-induced colitis. Figure 3C ~H is a representative of 3 independent experiments, Figure 3K , L are representatives of 2 independent experiments. Figure 3C Data of ~H and L are expressed as mean ± SD. *p < 0.05, ***p < 0.001. RNA-seq analysis ( Figure 3A ) Colonic gene expression in untreated or DSS-treated WT and Clec4a2- / - mice, and the expression levels are represented by heat maps.
[0043] Figure 3B It means in Figure 3A Results of pathway analysis in transfer products whose expression changed after DSS treatment. Samples from n=5 mice in each group were pooled for analysis. Figure 3C J) On day 12 after the start of DSS administration, total RNA was extracted from the colon of separately housed WT and Clec4a2- / - mice, and the expression of each gene was measured by real-time PCR.
[0044] Figure 3C The graph shows the expression level of the Tnfa gene after DSS treatment in WT and Clec4a2- / - mice (n=4).
[0045] Figure 3D The graph shows the expression level of Il1b after DSS treatment in WT and Clec4a2- / - mice (n=4).
[0046] Figure 3E The graph shows the expression level of Il6 in WT and Clec4a2- / - mice after DSS treatment (n=4).
[0047] Figure 3F The graph shows the expression level of Il17a after DSS treatment in WT and Clec4a2- / - mice (n=8).
[0048] Figure 3G The graph shows the expression level of Il17f in WT and Clec4a2- / - mice after DSS treatment (n=4).
[0049] Figure 3H The graph shows the expression level of Cxcl2 after DSS treatment in WT and Clec4a2- / - mice (n=8).
[0050] Fig. 3I The expression level of Cxcl2 in the colon was compared between untreated WT mice and Clec4a2- / - mice (n=5).
[0051] Figure 3J The expression level of Cxcl2 in the colon was compared in untreated or DSS-treated WT mice (n=5).
[0052] Figure 3K cLP cells were isolated from the colon of WT mice and Clec4a2- / - mice on day 12 after DSS administration, stimulated with PMA+ionomycin, and analyzed by flow cytometry for the proportion of IL-17 and IFN-γ-producing CD4+T cells or CD8+T cells (n=5 / group).
[0053] Figure 3L cLP cells were isolated from the colon of WT mice and Clec4a2- / - mice on day 12 after DSS administration, stimulated with PMA+ionomycin, and analyzed by flow cytometry for the proportion of IL-17 and IFN-γ-producing CD4+T cells, CD8+T cells, or γδT cells (n=5 / group).
[0054] Figure 4A ( Figure 4A (A) to (J) are graphs showing that the GM-CSF-Stat5 axis is activated in Clec4a2- / - mice after DSS treatment. Figure 4A ) After WT and Clec4a2- / - mice were treated with DSS, the expression level of the Csf2 gene encoding GM-CSF was detected by real-time PCR.
[0055] Figure 4B The expression level of Csf2 gene was detected by real-time PCR in WT mice without or after DSS treatment.
[0056] Figure 4CThe expression level of Csf2 mRNA was detected by real-time PCR in WT or Clec4a2- / - mice without DSS.
[0057] Figure 4D On day 12 after DSS administration, cLP CD45 was analyzed by flow cytometry + CD90.2 + CD3 - CD19 - CD11b-Gr1 + GATA3 in cells + ILC2 cells and RORγt + The proportion of ILC3 cells (n=5 / group).
[0058] Figure 4E On day 12 after DSS administration, cLP CD45 was analyzed by flow cytometry + CD90.2 + CD3 - CD19 - CD11b - Gr1 + RORγt + GM-CSF in ILC3 cells + The ratio of (n = 5 / group).
[0059] Figure 4F CD11b was isolated by MACS from the colon of mice not treated with DSS or from the colon of mice treated with DSS on days 7 and 12. + 5×10 cells were stimulated with TLR8 agonist (R848, 100 ng / ml) and TLR9 agonist (CpG-ODN, 100 ng / ml). 5 The cells were cultured for 4 hours, and the expression of Il1b was detected by real-time PCR (n=3 / group).
[0060] Figure 4G Total proteins were extracted from the colon of WT and Clec4a2- / - mice, and the expression levels of phosphorylated Stat5a (pStat5a) (90 kDa) and holo-Stat5a were measured by immunoblotting analysis (n=3 / group).
[0061] Figure 4H Yes means Figure 4G The ratio of pStat5a / Stat5a in .
[0062] Fig. 4I Analysis of CD11b in DSS-treated cLPs by flow cytometry + M2 macrophages (CD206 +CD11b + ) and M1 macrophages (Nos2 + CD11b + ) (WT: n=3, Clec4a2- / -: n=3).
[0063] Figure 4J Colon cells (1×10 6 After treatment with rmGM-CSF (0, 1, or 10 ng / ml) for 1 hour, proteins were extracted and the expression levels of pStat5a and total Stat5a were determined by immunoblotting analysis.
[0064] Figure 5A ( Figure 5A (Figure 1) is a graph showing that GM-CSF inhibits the onset of DSS-induced colitis. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Figure 5A ~C) WT mice were given 4% DSS for 7 days, followed by 5 days of normal water. Until the 6th day of DSS administration, PBS or rmGM-CSF (1 mg / mouse) was intraperitoneally administered every day. Figure 5A )Measure your body weight every day.
[0065] Figure 5B On the 12th day after the start of DSS administration, the mice were euthanized, the macroscopic pathology of the colon was confirmed, and the length of the colon was measured (n=5 / group).
[0066] Figure 5C On the 12th day after the start of DSS administration, total RNA was extracted from the colon of mice given PBS or rmGM-CSF, and the expression levels of Cxcl2, Tnf, Il17a, Il1b, Il6, Stat5a, Stat5b (n=5), Occludin, Zo1, and Claudin (n=4) were measured by real-time PCR.
[0067] Figure 5D Colon cells (5×10 5 4 cells were treated with rmGM-CSF (10 ng / ml) for 12 hours or left untreated, and the expression levels of Occludin, Zo1, and Claudin were measured by real-time PCR (n=4 / group).
[0068] Figure 5E ( Figure 5EH) WT and Clec4a2- / - mice were given 4% DSS for 7 days, followed by normal water for 5 days. Isotype antibody or anti-GM-CSF neutralizing antibody (100 μg) (Bio X Cell, USA, clone: MP1-22E9) was intraperitoneally administered on days -1, 1, 3, and 5 after DSS administration. The body weight and survival rate of WT and Clec4a2- / - mice were measured every day (n=5 / group). Figure 5E Indicates weight.
[0069] Fig. 5F It represents the survival rate.
[0070] Figure 5G On the 12th day after the start of DSS administration, the mice were euthanized, and the macroscopic pathology of the colon was confirmed and the length of the colon was measured.
[0071] Figure 5H On the 12th day after the start of DSS administration, total RNA was extracted from the colon of WT mice administered with isotype IgG or anti-GM-CSF antibody, and the expression levels of Il17a, Il6, Tnf, Il1b, Ifnb, Stat5, Il1a, Il10 and Cxcl2 were measured by real-time PCR (n=4 / group).
[0072] Fig.5I On day 12 after the start of DSS administration, total RNA was extracted from the colon of WT mice administered with isotype IgG or anti-GM-CSF antibody, and the expression levels of Zol1, Occludin, and Claudin were measured by real-time PCR (n=4 / group).
[0073] Fig. 6A This figure shows that the development of colon tumors induced by the AOM-DSS mouse model is suppressed in Clec4a2- / - mice by a method independent of resident bacteria. Fig. 6A ~H are representative of experiments performed four times independently. Fig. 6A The data of A, B, D, E, F, and H are expressed as mean ± SD. *p < 0.05; **p < 0.01; ***p < 0.001. ( Fig. 6A ~H) WT and Clec4a2- / - mice were bred separately to implement the AOM-DSS mouse model. Fig. 6A ) Body weight was measured every 3 days. Measured body weights are shown (WT: n=6, Clec4a2- / -: n=8).
[0074] Figure 6B The graph shows the survival rate (WT: n=6, Clec4a2- / -: n=8).
[0075] Figure 6CThese are images showing the intestine (WT: n=3, Clec4a2- / -: n=5).
[0076] Fig.6D The numbers are the size and number of colon tumors (WT: n=3, Clec4a2- / -: n=5).
[0077] Fig. 6E ( Fig. 6E WT and Clec4a2- / - mice were cohabited for 4 weeks and then subjected to the AOM-DSS mouse model. Fig. 6E ) Body weight was measured every 3 days. Measured body weights are shown (WT: n=5, Clec4a2- / -: n=5).
[0078] Fig. 6F The numbers are survival rates (WT: n=5, Clec4a2- / -: n=5).
[0079] Figure 6G These are images showing colon tumors (WT: n=3, Clec4a2- / -: n=5).
[0080] Figure 6H The numbers of colon tumors are shown (WT: n=3, Clec4a2- / -: n=5).
[0081] Fig. 7A ( Fig. 7A ~J) shows the expression of Clec4a2 and cytokines and the presence ratio of MDSC in polyp and non-polyp sites. Data are representative of 3 independent experiments and are expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. WT and Clec4a2- / - mice housed separately were treated with AOM-DSS, the colon was removed, and total RNA was extracted from the polyp and non-polyp parts of the colon. ( Fig. 7A ) The upper part shows the expression of Clec4a2 in the polyp and non-polyp parts of the colon of WT mice (n=8 / group), and the lower part shows the expression of CLEC4A in the tumor and non-tumor parts of colon cancer patients obtained from a public database (GSE20842, n=65).
[0082] Figure 7B The expression of Il17a in the polyp (p) and non-polyp (np) parts of the colon of WT and Clec4a2- / - mice was measured by real-time PCR (n=8 / group).
[0083] Figure 7C The expression of Il17f in the polyp (p) and non-polyp (np) parts of the colon of WT and Clec4a2- / - mice was determined by real-time PCR (n=8 / group).
[0084] Fig.7D The expression of Cxcl2 in the polyp (p) and non-polyp (np) parts of the colon of WT and Clec4a2- / - mice was determined by real-time PCR (n=8 / group).
[0085] Fig. 7E Heat maps are shown showing gene expression levels in polyp and non-polyp parts of the colon of WT or Clec4a2- / - mice analyzed by RNA-seq (n=5 / group, 5 samples in each group were set as one group).
[0086] Figure 7F WT and Clec4a2- / - mice were treated with AOM-DSS and the mononuclear cells in colon polyps and non-polyps were measured (CD11b + Ly6C + ) and granulocytic (CD11b + 6G + ) The presence ratio of bone marrow-derived immunosuppressive cells (MDSC) was expressed as a curve graph (WT: n=3, Clec4a2- / -: n=5).
[0087] Figure 7G Flow cytometry was used to measure the expression of mononuclear cells (CD11b + Ly6C + ) and granulocytic (CD11b + 6G + ) The presence ratio of bone marrow-derived immunosuppressive cells (MDSC) was expressed as a dot matrix (WT: n=3, Clec4a2- / -: n=5).
[0088] Figure 7H The expression intensity of Csf2 gene in the non-polyp (np) and polyp (p) sites of the colon of WT or Clec4a2- / - mice was measured by real-time PCR (WT: n=3, Clec4a2- / -: n=4).
[0089] Fig.7I The expression of Stat5a and Stat5b mRNA in the non-polyp (np) and polyp (p) sites of the colon of WT or Clec4a2- / - mice was measured by real-time PCR (WT: n=3, Clec4a2- / -: n=4).
[0090] Figure 7JProteins were extracted from non-polyps and polyps of WT and Clec4a2- / - mice, and the expression levels of pStat5a and holoStat5a proteins (90 kDa) were determined by immunoblotting analysis.
[0091] Fig. 8A ( Fig. 8A (F) is a graph showing that administration of anti-NA2 antibodies improves the onset of colitis. Data are expressed as mean ± SD. *p < 0.05, **p < 0.01. Fig. 8A ~E) indicates that WT mice were given 4% DSS for 7 days and then given normal water for 4 days. Anti-NA2 antibody (IgM, 200μg / mouse) and isotype immunoglobulin (IgM, 200μg / mouse) were intraperitoneally administered to WT mice every 3 days (days -1, 2, and 5) during the DSS administration period (n=5 / group). Fig. 8A ) indicates weight change.
[0092] Figure 8B Indicates the severity of the disease.
[0093] Figure 8C On the 11th day after the start of DSS administration, the mice were euthanized, the macroscopic pathology of the colon was confirmed, and the length of the colon was measured.
[0094] Fig.8D On day 11 after the start of DSS treatment, total RNA was prepared from the colon of mice administered with anti-NA2 antibody and isotype antibody, and the expression levels of Cxcl2, Il17a, Il6, Csf2, Stat5, and Il1b were measured by real-time PCR (n=5 / group).
[0095] Fig. 8E On the 11th day after the start of DSS administration, CD45 of cLP was measured by flow cytometry. + Ly6G in cells + CD11b + The proportion of neutrophils (n=5 / group).
[0096] Fig.8F WT mice were treated with AOM-DSS and anti-NA2 antibody or isotype. The number of colon tumors is shown by size.
[0097] Fig. 9AThe data indicate that anti-NA2 antibodies inhibit the binding between DCIR-NA2. 6_2_2, 6_3_3, etc. are different anti-NA2 monoclonal antibody clone names. Binding to NA2-OVA was observed in the wells to which only DCIR-Fc was added, but the binding was significantly reduced in the wells to which anti-NA2 antibodies were added. It can be seen that anti-NA2 antibodies inhibit the binding of DCIR-NA2. In the examples, 633_1G3 used in the treatment of colitis and intestinal tumors was re-cloned from the 6_3_3 clone, and the VDJ sequences of the 633_1G3 clone and the 6_3_3 clone were confirmed to be consistent.
[0098] Fig. 9B It is the result of ELISA which shows the binding of anti-NA2 antibody (633_1G3) to NA2.
[0099] Fig. 9C This indicates that the anti-NA2 antibody (633_1G3) selectively binds to the cell line expressing desialylated sugar chains among N-type sugar chains. Compared with wild-type CHO cells (more sugar chains with sialic acid at the non-reducing end), Lec1 cells (high mannose at the end), and Lec8 (agarose chains), the 633_1G3 antibody binds more strongly to Lec2 cells (desialylated sugar chains).
[0100] Fig.10 This is an example of the amino acid sequence and DNA sequence of the heavy chain variable region and light chain variable region of the anti-NA2 antibody.
[0101] Fig.11 This is a schematic diagram showing the binding test of anti-DCIR antibodies to mouse and human DCIR. Isotype or anti-DCIR antibodies are added to the well plate and allowed to stand overnight at 4°C to allow them to bind to the well plate. Block with PBS containing 10% (w / v) FCS, and add Fc, mouse DCIR-Fc, or human DCIR-Fc (5μg / ml). After standing at room temperature for 1 hour, the well plate is washed and the Fc or DCIR-Fc bound to the well plate is detected by Peroxidase-conjugated anti-human Fc (Jackson Immunoresearch). The detected Fc protein is initially bound by the antibody coated on the well plate, and the result can be used to evaluate the binding activity of the anti-DCIR antibody to mouse and human DCIR.
[0102] Fig.12 Indicates the binding activity of anti-DCIR antibodies to mouse and human DCIR. Fig.11 The anti-DCIR antibody showed binding activity to mouse DCIR-Fc and human DCIR-Fc.
[0103] Fig.13This indicates the inhibitory activity of anti-DCIR antibodies on the binding of NA2-expressing cells (Lec2) to DCIR. DCIR-Fc and isotype or anti-DCIR antibodies were added to Lec2 cells (desialylated sugar chains) and the effect on the binding of DCIR-Fc to Lec2 cells was measured. No changes were found in the binding of DCIR-Fc to Lec2 cells due to the addition of isotype antibodies, but it was found that the binding of DCIR-Fc to Lec2 cells by the antibody decreased in a concentration-dependent manner when anti-DCIR antibodies were added. Therefore, it was shown that anti-DCIR antibodies have the inhibitory activity on the binding of NA2-expressing cells (Lec2) to DCIR.
[0104] Fig.14A This is an example of the base sequence of the anti-DCIR antagonist antibody.
[0105] Fig. 14B This is an example of the amino acid sequence of an anti-DCIR antagonist antibody.
[0106] Fig.15A Myeloid cells from wild-type or DCIR-deficient mice were cultured with M-CSF (20 ng / mL) for 2 days, followed by M-CSF (20 ng / mL) and RANKL (100 ng / mL) for 4 days. Isotype or recombinant anti-DCIR antagonist antibody (5A3D8_recombinant) was added at 1 μg / mL at the start of culture and when the culture medium was replaced. After TRAP staining, TRAP-positive cells with a cell diameter of 100-200 μm and multinucleated cells with a diameter of more than 200 μm were counted as osteoclasts. Fig.15A These are microscopic images of osteoclasts in wild-type and DCIR-deficient mice after TRAP staining when the isotype or anti-DCIR antibody was added.
[0107] Fig. 15B The graph shows the number of osteoclasts with the indicated cell diameter (μm) in wild-type and DCIR-deficient mice. The graph shows the mean and standard deviation of the number of osteoclasts in four wells and was tested by student's t-test. *; p<0.05, iso VS anti-DCIR antibody. DETAILED DESCRIPTION
[0108] The following describes the forms of embodiments for implementing the present disclosure. However, the embodiments of the present disclosure are not limited to the following embodiments. In the following embodiments, unless otherwise specified, the constituent elements (including element steps, etc.) are not necessary. The numerical values and their ranges are also the same and do not limit the embodiments of the present disclosure.
[0109] In the present disclosure, in a numerical range expressed using “to”, the numerical values described before and after “to” are included as the minimum value and the maximum value, respectively.
[0110] In the numerical ranges described in stages in the present disclosure, the upper limit or lower limit described in one numerical range can be replaced by the upper limit or lower limit of the numerical range described in other stages. In addition, in the numerical ranges described in the present disclosure, the upper limit or lower limit of its numerical range can be replaced by the value shown in the embodiment.
[0111] In the present disclosure, each component may include a plurality of corresponding substances. When a plurality of substances corresponding to each component are present in the composition, unless otherwise specified, the content rate or content of each component refers to the total content rate or content of the corresponding plurality of substances present in the composition.
[0112] In the present disclosure, elements are expressed in the singular form, and unless explicitly stated otherwise, plural existence is not excluded unless there is a technical contradiction.
[0113] In the present disclosure, "treatment" of a disease includes eliminating or improving the symptoms of a disease or a concomitant disease, etc. In addition, "prevention" of a disease includes preventing the expression of symptoms of a disease or a concomitant disease, delaying the expression of symptoms of a disease or a concomitant disease, alleviating symptoms of a disease or a concomitant disease in advance, etc.
[0114] <Drug Composition>
[0115] In this study, the inventors found that the onset and development of inflammatory bowel disease and intestinal tumors are promoted by the action of dendritic cell immune receptor (DCIR). Therefore, a pharmaceutical composition containing a binding inhibitor between dendritic cell immune receptor (DCIR) and double-stranded desialylated N-type sugar chain (NA2) (hereinafter also referred to as DCIR-NA2 binding inhibitor) or DCIR inhibitor, and a pharmaceutically acceptable carrier for treating or preventing these diseases is advocated.
[0116] DCIR (gene symbol: Clec4a2) is a type of myeloid C-type lectin receptor containing ITIM in the cytoplasmic domain. The research group of the inventors and others has previously reported that DCIR recognizes double-stranded desialylated N-type sugar chains (NA2) and inhibits the differentiation and activation of dendritic cells (Haibu et al., J. Exp. Med., 218 (12), e20210435, 2021). The inventors and others found that if the DCIR signal is blocked, the GM-CSF-Stat5 signaling pathway is enhanced, thereby improving diseases such as inflammatory bowel disease and intestinal tumors.
[0117] The inventors examined the role of DCIR in the development of dextran sulfate sodium (DSS)-induced colitis and azoxymethane (AOM)-induced colon tumors in mice. DSS-induced colitis is an animal disease model of human ulcerative colitis and Crohn's disease. AOM-DSS-induced tumors are a model of colon cancer, which induces proton codon mutations in the K-ras gene, β-Catenin gene, etc., causing colon polyps, thereby promoting tumor formation through inflammation caused by DSS. The results showed that Clec4a2 - / - Mice were resistant to DSS-induced colitis compared with wild-type (WT) mice. - / - In mice, it inhibited the formation of AOM-DSS-induced intestinal tumors, a model of colon cancer. - / - The phenotype of mice was also mild when they were housed with WT mice, so it is believed that Clec4a2 - / - The mouse phenotype is independent of intestinal microbiota. - / - In the colon of mice, the expression of GM-CSF and the phosphorylation of its downstream Stat5 were enhanced, which inhibited the expression of Il17a and Cxcl2, and suppressed the infiltration of neutrophils and myeloid-derived suppressor cells. In addition, if mice were given recombinant GM-CSF, the expression of Il17a was effectively inhibited, and DSS-induced colitis was improved. On the other hand, if anti-GM-CSF antibodies were given, the symptoms were significantly worsened. Furthermore, anti-NA2 antibodies against NA2, the ligand of DCIR, inhibited the occurrence of colitis and colon tumors by inhibiting the action of NA2 on DCIR. These observations suggest that the action of DCIR can aggravate diseases such as colitis or colon tumors, and that DCIR-NA2 binding inhibitors are useful for treating or preventing the aggravation of these diseases caused by these DCIR. It is further shown that DCIR inhibitors that inactivate DCIR are useful for the treatment or prevention of these diseases.
[0118] The inventors have found that the DCIR-NA2 axis plays a role in controlling the immune response induced by natural immune receptors such as TLR8 and TLR9 in the intestine. Under physiological conditions, DCIR controls the excessive differentiation and activation of DCs to prevent autoimmunity. However, in the intestine, since the DCIR signal controls the natural immune signal and inhibits the induction of GM-CSF, the intestine becomes vulnerable to inflammation and tumor formation. Therefore, by inhibiting the activation of DCIR, intestinal inflammation and tumor formation can be inhibited via the natural immune mechanism.
[0119] A DCIR-NA2 binding inhibitor is a substance that inhibits (including reducing binding) the binding of DCIR and NA2. A DCIR inhibitor is a substance that inactivates DCIR. In one embodiment, a DCIR-NA2 binding inhibitor or a DCIR inhibitor may also be an antibody. In one embodiment, a DCIR-NA2 binding inhibitor may also be an anti-NA2 antibody. In one embodiment, a DCIR-NA2 binding inhibitor or a DCIR inhibitor may also be an anti-DCIR antibody.
[0120] Regarding the DCIR-NA2 binding inhibitor, inhibition of the binding between DCIR and NA2 can be confirmed by a method based on the method described in detail in the sections of anti-NA2 antibody and anti-DCIR antibody described later.
[0121] Regarding the DCIR inhibitor, inactivation of DCIR can be confirmed by the method described in detail in the section on anti-DCIR antibodies.
[0122] The anti-NA2 antibody and anti-DCIR antibody that may also be included in the pharmaceutical composition of the present disclosure are described in detail below.
[0123] - Anti-NA2 Antibodies -
[0124] Anti-NA antibodies are antibodies that specifically bind to NA2. Anti-NA2 antibodies can be antibodies that inhibit the binding between DCIR and double-stranded asialo N-type sugar chains. NA2 is a double-stranded asialo N-type sugar chain that is a ligand for DCIR. As NA2, the sugar chain having the structure represented by the following formula (wherein, sialic acid is not present at the two non-reducing ends of the structure of the following formula (A), and x and y are independently 3 or 4) as the basic structure can be listed.
[0125] [Chemistry 1]
[0126]
[0127] The anti-NA2 antibody specifically binds to NA2 having a sugar chain with the structure represented by the above formula as the basic structure, and having a branch chain at any position of the above basic structure, or fucose may be added. Wherein, there is no sialic acid at the two non-reducing ends of the above structure. As examples of such sugar chain structures, the following sugar chains can be cited.
[0128] [Formula 2]
[0129]
[0130] [Chemistry 3]
[0131]
[0132] [Chemistry 4]
[0133]
[0134] The NA2s represented by the above formulas are all ligands of DCIR, and it is considered that antibodies binding to these NA2s inhibit the binding of DCIR to these NA2s.
[0135] Anti-NA2 antibodies can also be antibodies that recognize NA2-modified proteins (including peptides) or other NA-modified polymer compounds. As NA2-modified proteins, NA2-modified bovine serum albumin (BSA), ovalbumin (OVA), transferrin, etc. can be listed. As NA2-modified polymer compounds, NA-modified polyallylamine (PAA) can be listed. Substances in which the reducing end of the sugar chain structure of NA2 is bound to these proteins or other polymer compounds can be used.
[0136] NA2 can be obtained by collecting from organisms, producing by genetic engineering methods, producing by organic synthetic chemistry methods, etc. In addition, NA2 can also be produced from commercially available materials. It can be produced by treating with neuraminidase (for example, in the case of PAA modified derivatives, company name: GlycoTech Co., trade name: Multivalent Biotinylated Polymer (Structure:
[0137] (SA2-6G-GN-M)2-3,6-M-GN-GNβ-PAA-biotin, wherein SA=Neu5Ac, G=Gal, GN=GlcNAc, M=Man, sp=-NHCOCH2NH-) to obtain NA2. Therefore, NA2 may also have a sugar chain structure represented by (G-GN-M)2-3,6-M-GN-GNβ-.
[0138] NA2 can be derived from an organism or a non-organism. In the case where NA2 is derived from an organism, NA2 can also be derived from a glycoprotein (including a glycopeptide) of the organism. As glycoproteins, the above examples can be cited. The details of NA2 can be referenced, for example, to International Publication No. 2016 / 006700.
[0139] In one embodiment, the anti-NA2 antibody has at least one selected from the group consisting of heavy chain CDR1 to 3, light chain CDR1 to 3, heavy chain FR1 to 4, and light chain FR1 to 4 of the following sequences.
[0140] In one embodiment, the anti-NA2 antibody has all of the heavy chain CDR1 to 3 of the following sequences.
[0141] In one embodiment, the anti-NA2 antibody has all of the light chain CDR1 to 3 of the following sequences.
[0142] In one embodiment, the anti-NA2 antibody has all of the heavy chain FR1 to FR4 of the following sequences.
[0143] In one embodiment, the anti-NA2 antibody has all of the light chain FR1 to FR4 of the following sequences.
[0144] In one embodiment, the anti-NA2 antibody has all of the heavy chain CDR1 to 3 and all of the light chain CDR1 to 3 of the following sequences.
[0145] In one embodiment, the anti-NA2 antibody has all of the heavy chain FR1 to 4 and all of the light chain FR1 to 4 of the following sequences.
[0146] In one embodiment, the anti-NA2 antibody has all heavy chain CDR1-3, all light chain CDR1-3, all heavy chain framework (FR) 1-4, and all light chain FR1-4 of the following sequences.
[0147] The base sequence of each region of the anti-NA2 antibody in one embodiment and the corresponding amino acid sequence are shown below.
[0148] Heavy chain FR1 (SEQ ID NO: 51)
[0149] gaggtgaagcttctcgagtctggaggtggcctggtgcagcctggaggatccctgaaactctcctgtgcag cctca
[0150] Heavy chain CDR1 (SEQ ID NO: 52)
[0151] ggattcgattttagtagatactgg
[0152] Heavy chain FR2 (SEQ ID NO: 53)
[0153] atgagttgggtccggcaggctccagggaaagggctagaatggattggagaa
[0154] Heavy chain CDR2 (SEQ ID NO: 54)
[0155] attaatccagatagcagtacgata
[0156] Heavy chain FR3 (SEQ ID NO: 55)
[0157] aactatacgccatctctaaaggataaattcatcatctccagagacaacgccaaaaatacgctgtacctgca aatgagcaaagtgagatctgaggacacagccctttattactgt
[0158] Heavy chain CDR3 (SEQ ID NO: 56)
[0159] gcaagacctgatgggacgatttattactacggttgctggtacttcgatgtc
[0160] Heavy chain FR4 (SEQ ID NO: 57)
[0161] tggggcgcagggaccacggtc
[0162] Light chain FR1 (SEQ ID NO: 58)
[0163] gatgttgtgatgacccaaactccactctccctgcctgtcagtctgggagatcaagcctccatctcttgcaga tctagt
[0164] Light chain CDR1 (SEQ ID NO: 59)
[0165] cagagtcttgcacacagtaatggaaacacctat
[0166] Light chain FR2 (SEQ ID NO: 60)
[0167] ttacattggtacctgcagaagccaggccagtctccaaagctcctgatctac
[0168] Light chain CDR2
[0169] aaaatttcc
[0170] Light chain FR3 (SEQ ID NO: 61)
[0171] aaccgattttctggggtcccagacaggttcagtggcagtggatcaggacacagatttcacactcaagatca gcagagtggaggctgaggatctgggagtttatttctgc
[0172] Light chain CDR3 (SEQ ID NO: 62)
[0173] tctcaaagtacacatgttccgtggacg
[0174] Light chain FR4 (SEQ ID NO: 63)
[0175] ttcggtggaggcaccaagctggaaatcaaa
[0176] Heavy chain FR1 (SEQ ID NO: 64)
[0177] EVKLLESGGGLVQPGGSLKLSCAAS
[0178] Heavy chain CDR1 (SEQ ID NO: 65)
[0179] GFDFSRYW
[0180] Heavy chain FR2 (SEQ ID NO: 66)
[0181] MSWVRQAPGKGLEWIGE
[0182] Heavy chain CDR2 (SEQ ID NO: 67)
[0183] INPDSSTI
[0184] Heavy chain FR3 (SEQ ID NO: 68)
[0185] NYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYC
[0186] Heavy chain CDR3 (SEQ ID NO: 69)
[0187] ARPDGTIYYYGCWYFDV
[0188] Heavy chain FR4 (SEQ ID NO: 70)
[0189] WGAGTTV
[0190] Light chain FR1 (SEQ ID NO: 71)
[0191] DVVMTQTPLSLPVSLGDQASISCRSS
[0192] Light chain CDR1 (SEQ ID NO: 72)
[0193] QSLAHSNGNTY
[0194] Light chain FR2 (SEQ ID NO: 73)
[0195] LHWYLQKPGQSPKLLIY
[0196] Light chain CDR2
[0197] KIS
[0198] Light chain FR3 (SEQ ID NO: 74)
[0199] NRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFC
[0200] Light chain CDR3 (SEQ ID NO: 75)
[0201] SQSTHVPWT
[0202] Light chain FR4 (SEQ ID NO: 76)
[0203] FGGGTKLEIK
[0204] Fig.10 An example of the DNA sequence (SEQ ID NO: 77 and SEQ ID NO: 78, respectively) and amino acid sequence (SEQ ID NO: 79 and SEQ ID NO: 80, respectively) of the heavy chain variable region and light chain variable region of the anti-NA2 antibody.
[0205] Heavy chain variable region (SEQ ID NO: 77)
[0206] gaggtgaagcttctcgagtctggaggtggcctggtgcagcctggaggatccctgaaactctcctgtgcagcctcaggattcgattttagtagatactggatgagttgggtccggcaggctccagggaaagggctagaatggattggagaaattaatccagatagcagtacgataaactat acgccatctctaaaggataaattcatcatctccagagacaacgccaaaaatacgctgtacctgcaaatgagcaaagtgagatctgaggacacagccctttattactgtgcaagacctgatgggacgatttattactacggttgctggtacttcgatgtctggggcgcagggaccacggtc
[0207] Light chain variable region (SEQ ID NO: 78)
[0208] gatgttgtgatgacccaaactccactctccctgcctgtcagtctgggagatcaagcctccatctcttgcagatctagtcagagtcttgcacacagtaatggaaacacctatttacattggtacctgcagaagccaggccagtctccaaagctcctgatctacaaaaatt tccaaccgattttctggggtcccagacaggttcagtggcagtggatcagggacagatttcacactcaagatcagcagagtggaggctgaggatctgggagtttatttctgctctcaaagtacacatgttccgtggacgttcggtggaggcaccaagctggaaatcaaa
[0209] Heavy chain variable region (SEQ ID NO: 79)
[0210] EVKLLESGGGLVQPGGSLKLSCAASGFDFSRYWMSWVRQAPGKGLEWIGEINPDSSTINYTPSLKDKFIISRDNAKNTLYLQMSKVRSEDTALYYCARPDGTIYYYGCWYFDVWGAGTTV
[0211] Light chain variable region (SEQ ID NO: 80)
[0212] DVVMTQTPLSLPVSLGDQASISCRSSQSLAHSNGNTYLHWYLQKPGQSPKLLIYKISNRFSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK
[0213] Furthermore, anti-NA2 antibodies are not limited to Fig.10 The antibody having the sequence of may be any antibody that shows binding activity to NA2 and has the ability to inhibit the binding of NA2 and DCIR. Various antibodies that show binding activity to NA2 and have the ability to inhibit the binding of NA2 and DCIR can be prepared by professionals in the field according to the methods described in the present disclosure and known antibody acquisition techniques. In addition, it is known that humans have NA2, which has the same sugar chain as mouse NA2, and mouse anti-NA2 antibodies are also effective against humans.
[0214] For example, the anti-NA2 antibody may be an antibody having a heavy chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more with SEQ ID NO: 79. The anti-NA2 antibody may be an antibody having a light chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more with SEQ ID NO: 80. In addition, the anti-NA2 antibody may be an antibody having heavy chain CDR1 to 3, light chain CDR1 to 3 of the above sequences, or a combination thereof, and having a heavy chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more with SEQ ID NO: 79, and having a light chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more with SEQ ID NO: 80. The anti-NA2 antibody can also be an antibody having heavy chain CDR1-3, light chain CDR1-3, or a combination thereof of the above-mentioned sequences, and having a heavy chain variable region with more than 90% amino acid sequence identity with sequence number 79, and having a light chain variable region with more than 90% amino acid sequence identity with sequence number 80.
[0215] In the present disclosure, the "identity" of an amino acid sequence refers to the ratio of the number of consistent amino acid residues to the number of all amino acid residues when aligning two amino acid sequences by inserting appropriate gaps on one or both sides as required in order to maximize the number of consistent amino acid residues. Alignment can be performed using known alignment tools such as BLAST, FASTA, CLUSTAL W. For example, alignment can be evaluated using the default parameters of BLAST.
[0216] The binding activity of anti-NA2 antibodies was confirmed according to the following steps. Ovalbumin (OVA) or NA2-OVA (10 μg / ml) was coated on a 96-well plate, left to stand overnight at 4°C and the antigen was coated on the plate. Afterwards, the plate was washed and blocked with PBS containing 10% (w / v) FCS at room temperature for 1 hour. Next, the plate was washed, the isotype antibody or anti-NA2 antibody was added and left to stand at room temperature for 1 hour. After washing the plate, the isotype antibody was detected using a labeled antibody. Specifically, the binding activity of the anti-NA2 antibody was confirmed by the method described in the example.
[0217] The ability of the anti-NA2 antibody to inhibit the binding between NA2 and DCIR was confirmed by the following procedure.
[0218] Add NA2-OVA or OVA (10 μg / ml) to the bottom of a 96-well plate and let it stand overnight at 4°C to allow it to bind to the wells. Block with PBS containing 10% (w / v) FCS, add Fc or DCIR-Fc (5 μg / ml), and anti-NA2 antibody. Let stand at room temperature for 1 hour, wash the plate, and detect Fc or DCIR-Fc bound to the wells using Peroxidase-conjugated anti-human Fc (Jackson Immunoresearch). Specifically, the ability of anti-NA2 antibodies to inhibit the binding of NA2 and DCIR was confirmed by the method described in the Examples ( Fig. 9A ).
[0219] Anti-NA2 antibodies can be prepared by any suitable method. For example, anti-NA2 antibodies can be prepared in vivo, in cultured cells, in vitro translation reactions, recombinant DNA expression systems, etc. In addition, anti-NA2 antibodies can be prepared by immunizing nude mice with hybridomas that produce monoclonal antibodies and purifying them from ascites.
[0220] The isotype of the anti-NA2 antibody may be, for example, IgG, IgM, IgA, IgD, or IgE, but is most preferably IgM.
[0221] Anti-NA2 antibodies can be full-length antibodies or low-molecular antibodies such as antibody fragments that specifically bind to NA2. Antibody fragments include Fab, Fab', F(ab')2, scFv, bispecific antibodies, etc. As a method for obtaining these antibody fragments, it is sufficient to construct genes encoding these antibody fragments, introduce them into expression vectors, and express them in appropriate host cells.
[0222] In addition, the anti-NA2 antibody can also be a modified antibody. As a modified antibody, an antibody bound to various molecules such as polyethylene glycol (PEG) or biotin can also be used. Such a modified antibody can be obtained by chemically modifying the obtained antibody. In addition, the modification method of the antibody can use a method known in the art.
[0223] The anti-NA2 antibody may be a polyclonal antibody, a monoclonal antibody, or an antibody derivative such as an antibody that retains the ability to specifically bind to an antigenic determinant.
[0224] Polyclonal antibodies can be obtained by isolating antiserum containing antibodies from GalT-deficient mice immunized with NA2 derivatives and screening for antibodies having the desired specificity using known methods such as NA2 sugar chain ELISA analysis and staining of asialo sugar chain-expressing cells.
[0225] As a method for making monoclonal antibodies and hybridomas, a method designed for making this antibody can be adopted from known methods. For example, a NA2-BSA derivative combining 10 or more NA2 molecules with BSA is used as an immunogen, and immunization is performed by subcutaneously injecting NA2-BSA complex (GT-111157, manufactured by Sugar Chain Engineering Research Institute) into mice that do not contain desialylated sugar chains in vivo due to the lack of galactosyl transferase sugar chain transferase (GalT1-deficient mice). In addition, wild-type animals can also be immunized. An adjuvant (Titer max gold; manufactured by TiterMax USA, Inc.) can also be used during immunization. As such an adjuvant, an adjuvant known in the art can be used.
[0226] Monoclonal antibodies can be obtained by removing spleen cells from immunized animals, fusing them with diffuse cells, and making hybridoma cells that produce monoclonal antibodies. Use known methods such as ELISA analysis of NA2 sugar chains and OVA combined with 96-well plates, and staining detection combined with desialylated sugar chain expression cell lines (Lec2 cells) to select hybridoma cells that produce antibodies that recognize the target NA2 sugar chains. Clone hybridomas that secrete the desired antibodies, culture them under appropriate conditions, and recover the secreted antibodies. They can be purified by known methods such as ion exchange columns, affinity chromatography, and protein L-bound beads. In addition, hybridomas can be transplanted into immunodeficient mice, and the ascites containing the secreted antibodies can be recovered and purified in the same way. In addition, based on the sequence of the BCR VDJ region obtained, it is possible to achieve: the production of antibodies in cultured cells, the manufacture of human monoclonal antibodies using the Alisma mouse strain (see Green, J. Immunol. Methods 231: 11-23, 1999; Wells, Eek, Chem Biol 2000 Aug; 7(8): R185-6), and the production of monoclonal antibodies based on phage display without immunization.
[0227] As anti-NA2 antibodies, mouse antibodies, human antibodies, rat antibodies, rabbit antibodies, sheep antibodies, camel antibodies, triple antibodies, etc. can be used, and genetically modified antibodies (e.g., chimeric antibodies, humanized antibodies, etc.) artificially altered for the purpose of reducing heterologous antigenicity to humans can also be used. As anti-NA2 antibodies, mouse antibodies, chimeric antibodies, humanized antibodies, and human antibodies are preferred, and humanized antibodies are more preferred.
[0228] Chimeric antibodies are antibodies composed of the variable regions of the heavy and light chains of mammals other than humans, such as mice, and the constant regions of the heavy and light chains of human antibodies. They can be obtained by linking DNA encoding the variable regions of mouse antibodies with DNA encoding the constant regions of human antibodies, integrating them into an expression vector and introducing them into a host for production.
[0229] Humanized antibodies are antibodies in which the complementarity determining regions (CDRs) of mammals other than humans, such as mouse antibodies, are transplanted to the complementarity determining regions of human antibodies, and their common gene recombination methods are also known. Specifically, a DNA sequence designed to link the CDR of mouse antibodies to the framework region (FR) of human antibodies is synthesized from several oligonucleotides made in a manner having a portion overlapping with the terminal portion by the PCR method. The obtained DNA is linked to the DNA encoding the constant region of human antibodies, then, integrated into an expression vector, and introduced into a host for production, and can be obtained. The FR of the human antibodies linked via CDR selects to form a good antigen binding site in the complementarity determining region. As needed, the amino acids in the framework region of the variable region of the antibody can also be replaced to form a suitable antigen binding site in the complementarity determining region of the humanized antibody (Sato, K.et al., Cancer Res, 1993, 53, 851-856.).
[0230] Human antibodies can also be produced using known methods. For example, human lymphocytes can be sensitized in vitro with cells expressing the desired antigen or the desired antigen, and the sensitized lymphocytes can be fused with human diffuse cells such as U266 to obtain the desired human antibodies that have binding activity to the antigen. In addition, the desired human antibodies can be obtained by immunizing transgenic animals with all receptors of human antibody genes with the desired antigen. Furthermore, the technology of obtaining human antibodies by panning using a human antibody library is also known. For example, the variable region of a human antibody can be expressed on the surface of a phage as a single-chain antibody (scFv) by phage display, and phages that bind to the antigen can be selected. If the genes of the selected phage are analyzed, the DNA sequence encoding the variable region of the human antibody that binds to the antigen can be determined. Since the DNA sequence of the scFv that binds to the antigen is clear (for example, refer to Fig.10 ), therefore, the sequence can be made into an appropriate expression vector to obtain human antibodies. Methods for making antibodies based on DNA sequences are well known.
[0231] - Anti-DCIR Antibody -
[0232] Anti-DCIR antibodies are antibodies that specifically bind to DCIR. DCIR is a member of the CLR family and is a membrane protein that has a sugar chain recognition domain outside the cell and an immunosuppressive tyrosine motif (ITIM) inside the cell. Anti-DCIR antibodies can be antibodies that inhibit the binding between DCIR and NA2, or they can be inhibitory antibodies that weaken or inactivate the effect of DCIR. For example, anti-DCIR antagonist antibodies are preferred. Anti-DCIR antagonist antibodies can be competitive antagonist antibodies that compete with NA2, or they can be non-competitive antagonist antibodies.
[0233] The binding activity of the anti-DCIR antibody can be confirmed by the following procedures.
[0234] The binding activity to the DCIR-expressing cell line was determined as follows. Isotype or anti-DCIR antibody (10 μg / ml) was added to the DCIR-expressing cell line or empty cells (HEK293 cells), suspended, and allowed to stand on ice for 30 minutes. The cells were washed, and fluorescent substance-labeled anti-mouse IgM antibody (0.5 μg / ml) was added, and allowed to stand on ice for 30 minutes. The cells were washed, and the binding of the antibody to the cells was determined by flow cytometry. In addition, the binding activity to the DCIR protein was determined as follows. The isotype antibody or anti-DCIR antibody (5 μg / ml) was coated on a 96-well plate, and the wells were coated by standing at 4°C overnight. Thereafter, the wells were washed, and blocked with PBS containing 10% (w / v) FCS at room temperature for 1 hour. Next, the wells were washed, and Fc or DCIR-Fc protein (5 μg / ml) was added and allowed to stand at room temperature for 1 hour. After the plate was washed, HRP-labeled anti-human Fc antibody was used to detect the DCIR-Fc protein bound to the coated antibody.
[0235] The ability of an anti-DCIR antibody as a DCIR-NA2 binding inhibitor to inhibit the binding of NA2 to DCIR can be confirmed by the following procedure.
[0236] DCIR-Fc and anti-DCIR antibody or isotype antibody (10 μg / ml) were added to Lec2 cells expressing desialylated sugar chains (mainly NA2), suspended, and allowed to stand on ice for 30 minutes. The cells were washed, and the binding of DCIR-Fc protein to Lec2 cells was detected using fluorescently labeled anti-human Fc antibody.
[0237] The inactivation of DCIR by anti-DCIR antibodies, which are DCIR inhibitors, can be confirmed by the following steps. M-CSF and sRANKL are added to the myeloid cells of wild-type mice and cultured for one week. TRAP staining is performed and the TRAP-positive multinucleated cells are counted to evaluate the degree of osteoclast differentiation (50). Anti-DCIR antibodies are added to the differentiation induction system, the degree of osteoclast differentiation is measured, and the effect of osteoclasts on differentiation is evaluated by comparing with the case where isotype antibodies are added. Since the action of DCIR is found to inhibit the differentiation of osteoclasts, when osteoclast differentiation is promoted by anti-DCIR antibodies, it is believed that DCIR is inactivated and the inhibition of differentiation is lifted. The same experiment was carried out in parallel using myeloid cells from DCIR-deficient mice to confirm that anti-DCIR antibodies do not non-specifically inhibit the formation of osteoclasts.
[0238] The anti-DCIR antibody can be prepared by any appropriate method, for example, the anti-DCIR antibody can be prepared by culturing cells. More specifically, for example, the anti-DCIR antibody can be prepared by the following method.
[0239] The antibody was established according to the following steps. A DCIR-expressing cell line (a DCIR expression vector was introduced into HEK293 cells to express DCIR on the cell surface) was mixed with an immune adjuvant (Titer Max) and DCIR-deficient mice were immunized twice. When the antibody titer relative to DCIR was found to increase, the mice were euthanized. Spleen cells were collected and fused with diffuse cells according to conventional methods to prepare hybridoma cells, and a monoclonal library was prepared by limiting dilution. Next, DCIR-specific antibodies were identified based on their binding activity to DCIR-expressing cells and DCIR proteins. The established monoclonal antibody-producing hybridoma was adapted to serum-free culture medium, and finally the antibody was purified from the cell culture medium using Protein-L binding beads. It can also be humanized to achieve the purpose of administration to humans.
[0240] The forms of antibodies in anti-DCIR antibodies (isotype, full-length antibody or low-molecular-weight antibody, antibody modifications, polyclonal antibodies and monoclonal antibodies, origin of antibodies, and methods for preparing them) can be applied to the matters described in the items for anti-NA2 antibodies, in addition to matters specific to anti-NA2 antibodies.
[0241] In one embodiment, the anti-DCIR antibody has at least one selected from the group consisting of heavy chain CDR1 to 3, light chain CDR1 to 3, heavy chain FR1 to 4, and light chain FR1 to 4 of the following sequences.
[0242] In one embodiment, the anti-DCIR antibody has all of the heavy chain CDR1 to 3 of the following sequences.
[0243] In one embodiment, the anti-DCIR antibody has all of the light chain CDR1 to 3 of the following sequences.
[0244] In one embodiment, the anti-DCIR antibody has all of the heavy chain FR1 to FR4 of the following sequences.
[0245] In one embodiment, the anti-DCIR antibody has all of the light chain FR1 to FR4 of the following sequences.
[0246] In one embodiment, the anti-DCIR antibody has all of the heavy chain CDR1 to 3 and light chain CDR1 to 3 of the following sequences.
[0247] In one embodiment, the anti-DCIR antibody has all of the heavy chain FR1-4 and light chain FR1-4 of the following sequences.
[0248] In one embodiment, the anti-DCIR antibody has all of the heavy chain CDR1-3, light chain CDR1-3, heavy chain framework (FR) 1-4, and light chain FR1-4 of the following sequences.
[0249] The base sequence of each region of the anti-DCIR antibody (anti-DCIR antagonist antibody (5A3D8) BCR VDJ region sequence) in one embodiment and the corresponding amino acid sequence are shown below.
[0250] Heavy chain FR1 (SEQ ID NO: 81)
[0251] gaggtccagctgcagcagtctggacctgagctggtaaagcctggggcttcagtgaagatgtcctgcaaggcttct
[0252] Heavy chain CDR1 (SEQ ID NO: 82)
[0253] ggatacacattcactagctatgtt
[0254] Heavy chain FR2 (SEQ ID NO: 83)
[0255] atgcactgggtgaagcagaagcctgggcagggccttgagtggattggatat
[0256] Heavy chain CDR2 (SEQ ID NO: 84)
[0257] attaatccttacaatgatggtact
[0258] Heavy chain FR3 (SEQ ID NO: 85)
[0259] aagtacaatgagaagttcaaaggcaaggccacactgacttcagacaaatcctccagcaca
[0260] gcctacatggagctcagcagcctgacctctgaggactatgcggtctattactgt
[0261] Heavy chain CDR3 (SEQ ID NO: 86)
[0262] gcaagatcctacaagaggtacgactggtacccaaga
[0263] Heavy chain FR4 (SEQ ID NO: 87)
[0264] tggggcgcagggaccacggtc
[0265] Light chain FR1 (SEQ ID NO: 88)
[0266] gacattgtgatgacccagtctcaaaaattcatgtccacatcagtaggagacagggtcagc
[0267] gtcacctgcaaggccagt
[0268] Light chain CDR1 (SEQ ID NO: 89)
[0269] cagaatgtgggtactaat
[0270] Light chain FR2 (SEQ ID NO: 90)
[0271] gtagcctggtatcaacagaaaccagggcaatctcctaaagcactgatttac
[0272] Light chain CDR2 (SEQ ID NO: 91)
[0273] tcggcatcc
[0274] Light chain FR3 (SEQ ID NO: 92)
[0275] taccggtacagtggagtccctgatcgcttcacaggcagtggatctggggacagatttcact
[0276] ctcaccatcagcaatgtgcagtctgaagacttggcagagtatttctgt
[0277] Light chain CDR3 (SEQ ID NO: 93)
[0278] cagcaatataacagctatccgctcacg
[0279] Light chain FR4 (SEQ ID NO: 94)
[0280] ttcggtggaggcaccaagctggaaatcaaa
[0281] Heavy chain FR1 (SEQ ID NO: 95)
[0282] EVQLQQSGPELVKPGASVKMSCKAS
[0283] Heavy chain CDR1 (SEQ ID NO: 96)
[0284] GYTFTSYV
[0285] Heavy chain FR2 (SEQ ID NO: 97)
[0286] MHWVKQKPGQGLEWIGY
[0287] Heavy chain CDR2 (SEQ ID NO: 98)
[0288] INPYNDGT
[0289] Heavy chain FR3 (SEQ ID NO: 99)
[0290] KYNEKFKGKATLTSDKSSSTAYMELSSLTSEDYAVYYC
[0291] Heavy chain CDR3 (SEQ ID NO: 100)
[0292] ARSYKRYDWYPR
[0293] Heavy chain FR4 (SEQ ID NO: 101)
[0294] WGAGTTV
[0295] Light chain FR1 (SEQ ID NO: 102)
[0296] DIVMTQSQKFMSTSVGDRVSVTCKAS
[0297] Light chain CDR1 (SEQ ID NO: 103)
[0298] QNVGTN
[0299] Light chain FR2 (SEQ ID NO: 104)
[0300] VAWYQQKPGQSPKALIY
[0301] Light chain CDR2 (SEQ ID NO: 105)
[0302] SAS
[0303] Light chain FR3 (SEQ ID NO: 106)
[0304] YRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFC
[0305] Light chain CDR3 (SEQ ID NO: 107)
[0306] QQYNSYPLT
[0307] Light chain FR4 (SEQ ID NO: 108)
[0308] FGGGTKLEIK
[0309] Fig.14A and Fig. 14B An example of the DNA sequence (SEQ ID NO: 109 and SEQ ID NO: 110, respectively) and amino acid sequence (SEQ ID NO: 111 and SEQ ID NO: 112, respectively) of the heavy chain variable region and light chain variable region of an anti-DCIR antagonist antibody is shown.
[0310] Heavy chain variable region (SEQ ID NO: 109)
[0311] gaggtccagctgcagcagtctggacctgagctggtaaaagcctggggcttcagtgaagatgtcctgcaaggcttctggatacacattcactagctatgttatgcactgggtgaagcagaagcctgggcagggccttgagtggattggatatattaatccttacaatgatggta ctaagtacaatgagaagttcaaaggcaaggccacactgacttcagacaaatcctccagcacagcctacatggagctcagcagcctgacctctgaggactatgcggtctattactgtgcaagatcctacaagaggtacgactggtacccaagatggggcgcagggaccacggtc
[0312] Light chain variable region (SEQ ID NO: 110)
[0313] gacattgtgatgacccagtctcaaaaattcatgtccacatcagtaggagacagggtcagcgtcacctgcaaggccagtcagaatgtgggtactaatgtagcctggtatcaacagaaaccagggcaatctcctaaagcactgatttactcggcatcctaccg gtacagtggagtccctgatcgcttcacaggcagtggatctgggacagatttcactctcaccatcagcaatgtgcagtctgaagacttggcagagtatttctgtcagcaatataacagctatccgctcacg,ttcggtggaggcaccaagctggaaatcaaa
[0314] Heavy chain variable region (SEQ ID NO: 111)
[0315] EVQLQQSGPELVKPGASVKMSCKAS GYTFTSYV
[0316] MHWVKQKPGQGLEWIGY INPYNDGTKY
[0317] NEKFKGKATLTSDKSSSTAYMELSSLTSEDYAVYYC ARSYKRYDWYPR
[0318] WGAGTTV
[0319] Light chain variable region (SEQ ID NO: 112)
[0320] DIVMTQSQKFMSTSVGDRVSVTCKAS QNVGTN
[0321] VAWYQQKPGQSPKALIY SAS
[0322] YRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFC QQYNSYPLT
[0323] FGGGTKLEIK
[0324] In addition, anti-DCIR antibodies are not limited to Fig.14A and Fig. 14BThe antibody having the sequence of can also be any antibody that shows binding activity to DCIR, inhibits DCIR, or has the ability to inhibit the binding of NA2 and DCIR. Various antibodies that show binding activity to DCIR, inhibit DCIR, or have the ability to inhibit the binding of NA2 and DCIR can be prepared by professionals in the field according to the methods described in the present disclosure and known antibody acquisition techniques.
[0325] For example, an anti-DCIR antibody may be an antibody having a heavy chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more to SEQ ID NO: 111. An anti-DCIR antibody may be an antibody having a light chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more to SEQ ID NO: 112. In addition, an anti-DCIR antibody may be an antibody having heavy chain CDR1 to 3, light chain CDR1 to 3 of the above sequences, or a combination thereof, and having a heavy chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more to SEQ ID NO: 111, and having a light chain variable region having an amino acid sequence identity of 80% or more, 85% or more, 90% or more, or 95% or more to SEQ ID NO: 112. The anti-DCIR antibody can be an antibody having heavy chain CDR1-3, light chain CDR1-3, or a combination thereof of the above-mentioned sequences, and having a heavy chain variable region having more than 90% amino acid sequence identity with sequence number 111, and having a light chain variable region having more than 90% amino acid sequence identity with sequence number 112.
[0326] The pharmaceutical composition disclosed herein is used to treat or prevent at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors. As inflammatory diseases, Crohn's disease, ulcerative colitis, etc. can be listed. As intestinal tumors, colon cancer, rectal cancer, small intestinal cancer, etc. can be listed. In autoimmune diseases such as collagen-induced arthritis (CIA) or experimental autoimmune encephalomyelitis (EAE), it is believed that inhibiting the binding between DCIR-NA2 or inhibiting DCIR will aggravate the disease, but it is shown in the present invention that in the colon, inhibiting the binding between DCIR-NA2 or inhibiting DCIR will inhibit inflammatory bowel disease and intestinal tumors. This is due to the presence of abundant innate immune lymphocyte 3 (ILC3) cells in the intestine, which are not found in other organs.
[0327] As pharmaceutically acceptable carriers for the pharmaceutical composition of the present disclosure, various commonly used organic or inorganic carrier substances can be cited, for example, excipients, lubricants, binders and disintegrants in solid preparations, solvents, cosolvents, suspending agents, isotonic agents, buffers, pain-relieving agents, etc. in liquid preparations. In addition, additives such as preservatives, antioxidants, colorants, sweeteners, adsorbents, wetting agents, etc. can also be used as needed.
[0328] The form of the pharmaceutical composition of the present disclosure is not particularly limited. The pharmaceutical composition of the present disclosure can be prepared by mixing, dissolving, granulating, tableting, emulsifying, encapsulating, freeze-drying, etc., the components for the pharmaceutical composition.
[0329] For example, the pharmaceutical composition of the present disclosure can be prepared for oral administration, and more specifically can be prepared into dosage forms such as tablets, pills, sugar-coated tablets, soft capsules, hard capsules, solutions, suspensions, emulsions, gels, syrups, slurries, and the like.
[0330] In addition, the pharmaceutical composition of the present disclosure can be prepared for non-oral administration, and more specifically, can be prepared into dosage forms such as injection solutions, suspensions, emulsions, creams, ointments, inhalants, suppositories, and the like.
[0331] The administration route of the pharmaceutical composition is not particularly limited. Examples of the administration route include oral administration, subcutaneous administration, intraperitoneal administration, intramuscular administration, eye drops, ear drops, nasogastric feeding, inhalation administration, transdermal administration, rectal administration, intramedullary administration, intravenous administration, surgical treatments such as indwelling, and the like.
[0332] The dosage and administration interval of the pharmaceutical composition are appropriately set according to the administration route, the symptoms, weight, physique, age, activity state of DCIR, etc. of the subject to be administered, the type and amount of the components used together, etc. In one embodiment, the pharmaceutical composition of the present invention is administered to a subject having at least one disease selected from the group consisting of inflammatory diseases and intestinal tumors in an amount and interval effective in treatment or prevention. The administration interval can be shorter than 1 day, once a day, or longer than 1 day.
[0333] According to one embodiment of the present disclosure, a method for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease or intestinal tumors is provided, comprising administering an effective amount of a DCIR-NA2 binding inhibitor or a DCIR inhibitor to a subject.
[0334] According to another aspect of the present disclosure, provided is a use of a DCIR-NA2 binding inhibitor or a DCIR inhibitor in the preparation of a medicament for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease or intestinal tumors.
[0335] According to another aspect of the present disclosure, there is provided a use of a DCIR-NA2 binding inhibitor or a DCIR inhibitor for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease or intestinal tumors.
[0336] In these aspects, at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors, the DCIR-NA2 binding inhibitor and the DCIR inhibitor, and their applicable scopes are the same as those described above.
[0337] [Example]
[0338] Next, the embodiments of the present disclosure will be specifically described using examples, but the embodiments of the present disclosure are not limited to these examples.
[0339] <Example 1>
[0340] 1. Introduction
[0341] Inflammatory bowel diseases (IBD) such as Crohn's disease (CD) and ulcerative colitis (UC) are chronic inflammatory diseases of the intestine and are the cause of colon tumors [1, 2]. Innate immune receptors such as C-type lectin receptors (CLR) and Toll-like receptors (TLR) expressed in the intestine not only protect the host against pathogens, but also recognize resident microorganisms and food ingredients and induce reactive oxygen species (ROS), antimicrobial proteins (AMPs), cytokines, chemokines, etc., and play an important role in the pathogenesis of IBD [3, 4]. In this way, in order to maintain intestinal homeostasis, a perfect balance between the resident microbiota and the mucosal immune system is necessary [4].
[0342] Based on this background, the inventors discovered that Dectin-1, a CLR that recognizes β-glucan, previously induced the antimicrobial protein S100A8 in the intestine by recognizing β-glucan in food, thereby inhibiting the proliferation of Treg-inducing bacteria, Lactobacillus murinus (L.murinus) [5]. Therefore, by blocking Dectin-1, the proliferation of L.murinus in the intestine is promoted, and Treg cells are increased, thereby inhibiting the onset of colitis [6]. In addition, another CLR, MGL1, expressed on colorectal squamous epithelial (cLP) macrophages, binds to Streptococcus and Lactobacillus species to induce IL-10, thereby improving chemical-induced colitis [7].
[0343] Dendritic cell immune receptor (DCIR; gene name Clec4a2) is another member of the CLR family and is mainly expressed in natural immune cells of the bone marrow, such as dendritic cells (DCs) and osteoclasts. DCIR is different from Dectin-1, which has a hemi-ITAM. It has an ITIM in the intracellular region and negatively regulates multiple signal transduction pathways by recruiting protein tyrosine phosphatase SHP-1[7-12].
[0344] Previously, the inventors reported that aged Clec4a2- / - mice spontaneously develop autoimmune sialadenitis and enthesitis [13, 14]. Clec4a2- / - mice are susceptible to autoimmune diseases such as collagen-induced arthritis (CIA) and experimental autoimmune encephalomyelitis (EAE) [13, 15]. In Clec4a2- / - mice, the DC population is expanded and the antigen-presenting ability of DC is enhanced, indicating that this enhancement of antigen-presenting ability is the cause of the autoimmunity and excessive response to antigenic stimulation in Clec4a2- / - mice [50, 13]. In addition, it was shown that granulocyte macrophage colony-stimulating factor (GM-CSF), known as colony-stimulating factor 2 (CSF2), caused DC from Clec4a2 to be activated. - / - The differentiation of mouse myeloid cells (BMCs) is promoted by the hyperphosphorylation of signal transducer and activator of transcription 5 (Stat5). Therefore, DCIR controls GM-CSF signaling by recruiting SHP-1 to ITIM and inhibiting the phosphorylation of downstream Stat5 [13, 16]. Thus, DCIR is also believed to be involved in intestinal inflammation and anti-tumor immunity. However, how DCIR participates in intestinal inflammation and tumor generation is still unclear.
[0345] In this study, the role of DCIR in the development of dextran sulfate sodium (DSS)-induced colitis and azoxymethane (AOM)-induced colon tumors in mice was examined. DSS-induced colitis is an animal disease model of human ulcerative colitis and Crohn's disease. AOM-DSS-induced tumors are a model of colon cancer, which induces proton codon mutations in the K-ras gene and β-catenin gene, causing colon polyps, thereby promoting tumorigenesis through inflammation caused by DSS. The results showed that Clec4a2 - / - Compared with wild-type (WT) mice, mice were less susceptible to DSS-induced colitis, and the expression of inflammatory cytokines and chemokines was suppressed, and these phenomena were not involved in the resident microbiota. - / -In mice, the formation of AOM-DSS-induced colon tumors was suppressed compared to WT mice, and the expression of Csf2 in polyps was increased. Furthermore, if anti-double-stranded desialylated N-type sugar chain antibody (anti-NA2 antibody) was administered, the onset of colitis and colon cancer was suppressed. Based on these results, it is believed that NA2, a ligand of DCIR, can be used as a target for the treatment and prevention of diseases aggravated by the action of DCIR.
[0346] 2. Materials and Methods
[0347] 2.1 Mice
[0348] Clec4a2 - / - The mice were prepared using the same recombinant technology and backcrossed with BALB / cA (Japan SLC Co., Ltd., Shizuoka, Japan) for 12 generations [1]. WT and Clec4a2 mice of similar age were used. - / - Male mice were housed in an environmentally controlled clean room at the Institute of Life and Medical Sciences, Tokyo University of Science, under specific pathogen-free conditions. All animal experiments were approved by the institutional animal use committee and performed in accordance with ethical guidelines for animal experimentation and safety guidelines for genetic manipulation experiments.
[0349] 2.2DSS-induced colitis and AOM-DSS-induced tumors
[0350] DSS-induced colitis was induced as follows. - / - Mice and WT mice were separated or cohabited (the cohabitation group was cohabited after weaning), and 4% DSS (36-50 kDa; MP Biomedicals, Illkirch, France) was added to the drinking water for 7 days, followed by recovery with normal water for 5 days.
[0351] Diarrhea and blood in stool were scored every 2 days as follows.
[0352] [Diarrhea] 0: Normal, 1: Slightly watery stool, 2: Loose stool, 3: Slightly watery diarrhea, 4: Watery diarrhea.
[0353] [Blood in stool] 0: normal, 2: slight bleeding, 3: moderate bleeding, 4: heavy bleeding.
[0354] Weight loss was scored as follows.
[0355] [Weight loss] 0: None, 1: Weight loss of more than 0% and less than 5%, 2: Weight loss of more than 5% and less than 10%, 3: Weight loss of more than 10% and less than 15%, 4: Weight loss of more than 15%.
[0356] The disease activity index was the average of these scores. The disease activity index was set as: (sum of scores for diarrhea, bleeding, and weight loss) / 3.
[0357] In Clec4a2 - / - During 4% DSS-induced colitis, PBS and rmGM-CSF (Petrotech, USA) (1 μg) were intraperitoneally administered to WT mice on days 0, 1, 2, and 3.
[0358] In WT mice, IgG2a isotype reference (Bio X Cell, USA, clone: 2A3) and anti-GM-CSF (Bio X Cell, USA, clone: MP1-22E9) neutralizing antibody (100 μg / mouse) were intraperitoneally administered on days 0, 1, 2, 3, 4, 5, and 6.
[0359] Anti-NA2 antibody (clone: 633_1G3, 200 μg / mouse) and isotype antibody (IgM, clone: MM-3, 200 μg / mouse) were intraperitoneally administered to WT mice on days 1, 2, and 5.
[0360] On the 12th day after the start of DSS administration, mice were euthanized and histopathological analysis was performed. Colon sections were washed with PBS, fixed with 10% neutral buffered formalin, and embedded in paraffin. After sectioning, tissue sections were stained with hematoxylin and eosin.
[0361] Anti-NA2 antibodies were generated by immunizing galactosyltransferase-1 (GalT1)-deficient mice with NA2 according to the following protocol. NA2 used for immunization is as follows.
[0362] Product Name: GT-11157
[0363] Company name: Sugar Chain Engineering Research Institute Co., Ltd.
[0364] Structure: NA2 sugar chains are bound to BSA through maleimide bonds, and 15 to 25 molecules of NA2 are bound to each BSA molecule.
[0365] Immunization was performed using the following process. NA2-BSA (1 mg / ml) and the adjuvant Titer Max Gold (registered trademark, TiterMax) were mixed in a 1:1 ratio, and 400 μL was subcutaneously inoculated into each GalT1-deficient mouse, followed by a booster inoculation of 200 μL 4 weeks later. Two weeks later, the mice were euthanized, and spleen cells were fused with myeloma (NS-1) cells to prepare hybridomas. A monoclonal library of hybridomas was prepared by limiting dilution, and a clone (633) producing NA2-specific antibodies was identified by the following method. Furthermore, in order to establish a monoclonal clone, it was cloned again, and the 633_1G3 clone was established. The CDR region sequences of clones 633 and 633_1G3 were obtained ( Fig.10 ), since 633 and 633_1G3 have the same sequence, they were confirmed to be monoclonal antibodies.
[0366] The 633_1G3 hybridoma was transplanted into nude mice pre-stimulated with pristane, and the mice were euthanized and the ascites was collected. Since 633_1G3 is an IgM antibody, the antibody was purified using CaptoL (Sigma Aldrich), a protein L-modified agarose bead.
[0367] The anti-NA2 antibody was identified by confirming the ability of DCIR-Fc to inhibit the binding of NA2 using the following process. NA2-OVA (GT-11204, Glycochain Engineering Research Institute, Inc.) or OVA (10 μg / ml) was added to the bottom of a 96-well plate and allowed to stand overnight at 4°C to bind to the plate. Blocked with PBS containing 10% FCS, Fc or DCIR-Fc (5 μg / ml) and culture medium from a hybridoma producing anti-NA2 antibodies were added. After standing at room temperature for 1 hour, the plate was washed and the Fc or DCIR-Fc bound to the plate was detected using Peroxidase-conjugated anti-human Fc (Jackson Immunoresearch). Fig. 9A ). The graph is represented by the mean value of triplicate +- standard deviation. In addition, in Example 1, DCIR-Fc refers to mouse DCIR-Fc unless otherwise specified.
[0368] Anti-NA2 antibody (clone 633, from which 633_1G3 was re-cloned, with the same BCR VDJ sequence) significantly inhibited the binding of the extracellular region of DCIR-human Fc fusion protein to NA2-OVA.
[0369] The ability of anti-NA2 antibodies to bind to NA2 was confirmed by the following procedure. Using the 633_1G3 antibody, ELISA ( Fig. 9B) and staining of LEC2 cell lines expressing desialylated sugar chains ( Fig. 9C ) confirmed the ability to bind to NA2.
[0370] ELISA is performed using the following process. OVA or NA2-OVA (10 μg / ml) is coated on a 96-well plate and allowed to stand overnight at 4°C to coat the wells with the antigen. Thereafter, the wells are washed and blocked with PBS containing 10% FC at room temperature for 1 hour. Next, the wells are washed, and isotype antibodies (iso) (10 μg / ml (10)) or 633_1G3 antibodies (0.1 μg / ml (0.1), 1 μg / ml (1) or 5 μg / ml (5)) are added and allowed to stand at room temperature for 1 hour. After the wells are washed, IgM antibodies are detected using Peroxidase-conjugated anti-Mouse IgM (Jackson Immunoresearch). The graph represents the average value of the wells that were performed in triplicate. The results are representative of two or more independent experiments.
[0371] Staining of the asialo sugar chain-expressing LEC2 cell line was performed using the following procedure. The binding of anti-NA antibody (633_1G3) to CHO cells and their sugar chain modification enzyme mutants Lec1 (expressing high mannose sugar chains), Lec8 (expressing agarose chains), and Lec2 (expressing asialo sugar chains) was analyzed. Isotype antibody (iso) or anti-NA antibody (633_1G3) (10 μg / ml) was added to each cell, and the cells were allowed to stand on ice for 30 minutes. After washing, PE / Cy7-conjugated anti-mouseIgM antibody (Biolegend) was added, and the cells were allowed to stand on ice for another 20 minutes. The cells were washed and analyzed using FACSCantoII.
[0372] RNA was purified from 633_1G3 clone hybridoma cells, cDNA was prepared, and DNA sequence analysis from FR1 to FR4 was performed. Fig.10 The amino acid sequence and analyzed DNA sequence of 633_1G3 are shown. Fig.10 In the figure, the upper half represents the sequence of the heavy chain (VH), and the lower half represents the sequence of the light chain (VL).
[0373] The induction of AOM-DSS-induced tumors was performed by the following process. According to body weight, female mice aged 7 to 8 weeks, which were cohabited or separated after weaning at 4 weeks of age, were injected with AOM (1 mg / ml) (10 mg / kg), treated with 2% DSS one week later, and then treated with normal water. After 3 cycles of the above-mentioned DSS and water treatment, water treatment was performed for 8 weeks. Body weight was measured every 3 days. Anti-NA2 antibody (clone: 633_1G3, 200 μg / mouse) and isotype antibody (IgM, clone: MM-3, 200 μg / mouse) were intraperitoneally administered to WT mice.
[0374] 2.3 Immunoblotting analysis
[0375] On the 12th day after administration of DSS and normal water, whole protein was extracted from the mouse colon using NP40 lysis buffer (Invitrogen, USA) and treated with phosphorylation inhibitor (Roche, Switzerland). Whole protein of polyps (2-3 per group) and non-polyps (tissue surrounding polyps) was extracted in the same manner as above. 6 Colonocytes were treated with rmGM-CSF (0, 1, 10 ng / ml) for 1 hour, and proteins were collected after stimulation. Rabbit anti-mouse Stat5 (D2O6Y) antibody, rabbit anti-mouse phosphorylated Stat5 (Try694) antibody (Cell Signaling Technology), and anti-rabbit IgG (H+L) antibody (ThermoFisher, USA) were used for blotting.
[0376] 2.4 Quantitative real-time RT-PCR and RNA sequencing (RNA-seq)
[0377] The cDNA of the bacterial flora was extracted from the feces of mice raised separately using the QIAmpDNA stool mini kit (QIAGEN, USA). Total mRNA was extracted from the colon, or 2 to 3 polyps and non-polyps of the colitis model using the GenElute mammalian RNA miniprep kit (Sigma-Aldrich, St. Louis, USA). The same amount of RNA from each sample was combined into one and RNA-seq was performed. The isolated RNA was reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, USA). The expression of messenger RNA of the displayed genes and the expression of each bacteria were measured by real-time quantitative PCR using SYBR premix Ex Taq (Takara Bio, Otsu, Japan) on the iCycler system (Bio-Rad, Hercules, USA). The relative value of each gene was calculated by the comparative Ct method and normalized by the expression level of Gapdh, and the relative value of each bacteria was calculated by the comparative Ct method and normalized by the expression level of 16S. Table 1A and Table 1B show primer lists.
[0378] Table 1A
[0379]
[0380] Table 1B
[0381]
[0382] 2.5 Preparation of colon or tumor cells
[0383] Mouse colon or 2-3 tumors (2-3 mm) were washed with phosphate buffered saline (PBS), cut into 2 mm slices, and then shaken at 37°C for 30 minutes in Hanks' balanced salt solution (HBSS) containing 3 mM ethylenediaminetetraacetic acid (EDTA). Subsequently, the cells were washed with 10% fetal calf serum (FCS) (Life Technologies), 400 U / ml collagenase (C2139;
[0384] The sections were suspended in RPMI (Life Technologies / Invitrogen, Carlsbad, California, USA) containing 5U / ml DNase 1 (Sigma-Aldrich) and 5U / ml DNase 1 (Sigma-Aldrich) and shaken at 37°C for 120 minutes. After the final incubation, pasteurization was performed for 30 seconds, and the single cell suspension was collected by filtering with sterilized gauze. After incubating epithelial cell adhesion molecule (EpCAM), CD4, CD8, CD49b, and CD19 microbeads (BD, USA) for 20 minutes, washed twice with MACS (registered trademark) buffer, and MACS (registered trademark) treatment was performed to screen negative cells. After incubating CD11b microbeads (BD, USA) for 20 minutes, washed twice with MACS (registered trademark) buffer, and MACS (registered trademark) treatment was performed to screen positive cells. In flow cytometry, cells were washed twice with FACS Hanks buffer (HBSS containing 2% FCS and 0.1% sodium azide) and then treated with 2.4G2 to block FcR binding. Subsequently, the cells were surface stained with the following 250-fold diluted fluorescence-conjugated antibodies: anti-mouse CD11b (M1 / 70), CD45 (30-F11), Ly6C (HK1.4), Ly6G (1A8), TCR-β (H57-597), CD3 (17A2), IL17A (TC11-18H10), Foxp3 (MF-14), IFN-γ (XMG1.2), GM-CSF (MP1-22E9), CD4 (GK1.5), CD8 (53-6.7), CD206 (C068C2), Nos2 (W16030C), RORγt (B2D), CD90.2 (30-H12), GATA3 (PC61), Gr1 (RB6-8C), etc. All antibodies were purchased from BioLegend (San Diego, CA, USA). To distinguish dead cells, 7-aminoactinomycin D (7-AAD) was added to all samples before application. Cells were collected using FACSCanto II (BD Biosciences) and data were analyzed using FlowJo 10.0 software (Tree Star, Ashland, OR, USA).
[0385] 2.6 Statistical analysis
[0386] The differences in parameter data were evaluated by student's t test. Statistics were calculated using PRISM7 software (GraphPad Software), and P values < 0.05 were considered statistically significant.
[0387] 3. Results
[0388] 3.1Clec4a2 - / - Mice showed resistance to DSS-induced colitis independent of changes in intestinal microbiota.
[0389] In order to clarify the role of DCIR in the development of colitis, first, the expression of the DCIR gene in the inflammatory local of colitis was studied. Since the expression of DCIR in the inflammatory local of DSS-induced colitis was measured, colitis was induced after 7 days of administration of water containing 4% DSS to mice. Thereafter, after being fed with normal drinking water until the 12th day, the mice were euthanized for analysis. In the colon of mice with colitis, the expression of the Clec4a2 gene was enhanced compared to the colon of healthy mice (Figure 1A). In addition, when the expression of the human DCIR gene was detected from the public GEO database of NCBI, enhanced expression of the DCIR gene was found in the colon of Crohn's disease and ulcerative colitis compared to healthy people ( Figure 1A-2 ). Clec4a2 - / - The weight loss and severity scores of colitis in mice were milder than those in WT mice both at the time of DSS administration and during the recovery period ( Figure 1B ). - / - In mice, inflammation-induced shortening of the colon was weaker than in WT mice ( Figure 1C ). Clec4a2 - / - The infiltration of inflammatory cells in the colon of mice was milder than that of WT mice. Regarding the damage of colon epithelial cells, Clec4a2 - / - No significant differences were observed between mice and WT mice ( Figure 1D ).
[0390] Next, to test the possibility that resident microorganisms could influence the function of DCIR, Clec4a2 - / - The mice were cohabited with WT mice for 4 weeks after weaning. Thereafter, under the cohabitation conditions, the mice were allowed to freely drink drinking water containing 4% DSS. - / - In mice, the symptoms caused by DSS, such as weight loss, diarrhea and blood in stool, shortening of the colon, and infiltration of inflammatory cells, were milder than those in WT mice ( Figure 1E In addition, nucleic acids were extracted from the feces of mice before and 4 weeks after cohabitation, and the composition of representative bacterial species in the intestinal flora was determined by real-time PCR of 16S rRNA sequences. The results are shown in Figure 1H and Fig. 1I These results show that Clec4a2 - / - There were differences in the composition of representative bacterial species in the intestinal flora of mice and WT mice before cohabitation, but the composition became very similar after cohabitation. These results show that Clec4a2 - / -Mice were resistant to DSS-induced colitis in a manner independent of the resident microbiota.
[0391] 3.2 Clec4a2 after DSS administration - / - In mice, the infiltration of regulatory T (Treg) cells was not reduced, while the infiltration of inflammatory cells was reduced.
[0392] To understand Clec4a2 - / - The mechanism of improvement of colitis in mice was determined by measuring the proportion of infiltrating cells in the colonic lamina propria (cLP). + Monocytes, Ly6G + The proportion of inflammatory cells such as neutrophils is increased in Clec4a2 - / - mice and WT mice ( Figure 2A , B). However, after 4% DSS treatment, the proportion of these cells increased significantly in WT mice, but not in Clec4a2 - / - There was no increase in mice ( Figure 2C , D). It is believed that the increase in these inflammatory cells is the cause of inflammation.
[0393] Treg cells play an important role in maintaining the homeostasis of the intestinal immune system. Since they inhibit the onset of DSS-induced colitis[6], the Treg cell population after DSS-induced colitis was also detected. + CD4 + T cells, CD8 + T cells and CD4 + Foxp3 + The proportion of T cells in WT mice and Clec4a2 - / - The mice were almost the same ( Figure 2E The expression levels of Foxp3, Tgfb, and Tbx21 in the colon were significantly higher than those in Clec4a2 - / - mice and WT mice ( Figure 2F These results indicate that: - / - In mice, even when DSS-induced colitis was induced, the presence of Treg cells and the ratio of Th1 and Th2 cells in cLP was not affected by the lack of DCIR.
[0394] 3.3 In Clec4a2 - / - In mice, the expression of inflammatory cytokines or chemokines such as Il17a and Cxcl2 was reduced.
[0395] Next, RNA-seq analysis was performed to examine gene expression in the colon at day 12 after DSS-induced colitis induction ( Figure 3A ). - / - In mice, the expression of inflammatory cytokines such as Tnf, Il6, Il1b, Il1a, and Ifn-g was reduced compared with WT mice. Il17f was not reduced. - / - In mice, the expression of Csf2 was enhanced, while that in WT mice was greatly reduced. Before DSS treatment, the expression of these genes was significantly increased in WT mice and Clec4a2 - / - In addition, the expression of chemokines and their receptors such as Cxcl2, Cxcl5, Cxcl9, Cxcl11, Cxcl15, Cxcr2, Ccl1, and Ccr3 was significantly different from that of Clec4a2. - / - In addition, it was found that Clec4a2 - / - In mice, the expression of transcription factors such as Stat5a and Stat5b is enhanced.
[0396] It is clear that when performing pathway analysis of RNA-seq data, - / - In the colon of mice, pathways related to inflammation or immune response, such as NF-κB, TNF, and IL-17 signaling pathways, were reduced ( Figure 3B ).
[0397] Subsequently, the expression of cytokines and chemokines was confirmed by real-time RT-PCR. - / - In mice, the expression of Tnf, Il1b, Il6, and Il17a was decreased compared with WT mice ( Figure 3C ~F). Figure 3C ~J. The expression of Il17f is in Clec4a2 - / - There was no decrease in mice ( Figure 3G In addition, the expression of Cxcl2, one of the chemokines, was not significantly increased in Clec4a2 cells without DSS treatment. - / - mice and WT mice were similar, but Clec4a2 - / - The expression of Figure 3H ~J). Then, the cells expressing these cytokines were analyzed. + When T cells were analyzed for cells expressing IL-17A, cells from CD4 + T cell IL-17A in Clec4a2 - / - Decreased in mice, from CD8 + There was no decrease in IL-17A in T cells ( Figure 3K and 3L ). The proportion of IFN-γ producing cLP-T cells in Clec4a2 - / - Mice also decreased ( Figure 3K and 3L ).
[0398] 3.4DCIR inhibited the expression of GM-CSF in ILC3 by inhibiting the expression of Il1b induced by TLR.
[0399] It can be seen that compared with WT mice, the Clec4a2 - / - Increased expression of Csf2, which encodes GM-CSF, in mice Figure 3A and 4A The expression of this gene was enhanced after DSS treatment ( Figure 4B and 4C GM-CSF is mainly produced by ILC3 in the colon after DSS treatment [44, 45]. + ILC2 cells and RORγt + The proportion of ILC3 cells was significantly different between WT mice and Clec4a2 - / - There was no variation in cLP between mice ( Figure 4D ). Compared with WT mice, - / - In mouse cLP, RORγt + GM-CSF in ILC3 cells + The proportion of cells increased ( Figure 4E ). The production of GM-CSF from ILC3s depends on the ability of macrophages to sense microbial signals and produce IL-1β
[45] . DCIR is a negative regulator of TLR8- and TLR9-mediated innate immune responses. In macrophages, when DCIR is activated, it inhibits the phosphorylation of Erk1 / 2, JNK1 / 2, and p38 and the production of TLR9-mediated IL-1β[46-47]. It can be seen that compared with WT mice, in Clec4a2 - / - Mouse colon CD11b + In cells, the relative expression of Il1b increased after stimulation with R848 and CpG-ODN ( Figure 4F ). It can be seen that the relative expression of Il1b decreased in the whole colon, while the relative expression of Clec4a2 decreased after 7 and 12 days of DSS administration. - / - Mouse colon CD11b + In cells, the expression of Il1b increased ( Figure 4F). These data suggest that DCIR regulates GM-CSF production by ILC3 cells through the microbial-mediated TLR signaling pathway. Furthermore, the inventors have previously reported that GM-CSF signals are transduced in myeloid cells via phosphorylation of Stat5
[13] . - / - The increased expression of GM-CSF in Clec4a2 mice - / - In the colon of mice, Stat5 phosphorylation is enhanced ( Figure 4G and 4H In addition, when colon cells were treated with recombinant mouse GM-CSF, the expression of Clec4a2 - / - Increased phosphorylation of Stat5 in mice ( Figure 4J ). In addition, it can be seen that in Clec4a2 - / - In the cLP of mice, compared with WT mice, the number of M2 macrophages increased and the number of M1 macrophages decreased ( Fig. 4I ).
[0400] 3.5GM-CSF inhibits the pathogenesis of DSS-induced colitis.
[0401] Next, the role of GM-CSF in the development of DSS-induced colitis was examined. During the administration of DSS, WT mice were given recombinant mouse GM-CSF and the development of colitis was examined. The results showed that the administration of GM-CSF enhanced the expression of Stat5 in the colon, reduced the expression of Il17a, Cxcl2, Il6, and Il1b, and effectively inhibited the development of DSS-induced colitis ( Figure 5A ~C). In addition, after administration of GM-CSF, the expression of close-adhesion components such as Occludin, Claudin, and Zo1 increased ( Figure 5C ). Furthermore, in the - / - In the colon cells of mice, the expression of Occludin, Claudin and Zo1 was more effectively enhanced by the administration of GM-CSF than that of cells from WT mice ( Figure 5D On the other hand, when anti-GM-CSF neutralizing antibody was administered, WT mice and Clec4a2 - / - The symptoms of DSS-induced colitis in both mice were aggravated ( Figure 5E In the colons administered with anti-GM-CSF antibody, the expression of Il17a, Il6, and Il1b increased, the expression of Stat5 decreased, and the expression of Cxcl2 was not affected compared with the isotype reference Ig ( Figure 5H In addition, when anti-GM-CSF antibodies were administered, the expression of Occludin, Claudin, and Zo1 was reduced ( Fig.5I). These results suggest that GM-CSF plays an important role in the regulation of colitis pathogenesis.
[0402] 3.6 AOM-DSS-induced colon tumor formation is regulated by Clec4a2 - / - In mice, it is suppressed by a process that is independent of resident bacteria.
[0403] Since DCIR plays an important role in the pathogenesis of colitis, we next examined the effect of Clec4a2 deficiency on colon tumorigenesis. - / - The mice were given AOM, and 7 days later, they were given water containing 2% DSS for 1 week and normal water for 2 weeks. After the DSS-normal water cycle was repeated 3 times, the mice were fed with normal water for 6 weeks. - / - In mice, weight loss was stable compared with WT mice, but there was no significant difference in survival rate ( Fig. 6A and 6B Compared with WT mice, the formation of tumors in the colon was significantly increased in Clec4a2 - / - Significantly reduced in mice ( Figure 6C and 6D ).
[0404] To examine the effects of intestinal flora, we expressed - / - In the fourth week after weaning, mice were first cohabitated with WT mice to induce tumors under cohabitation conditions. - / - The mice lost weight more steadily than WT mice, and their survival rate was significantly higher ( Fig. 6E and 6F ). In addition, in Clec4a2 - / - In mice, tumorigenesis was suppressed compared with WT mice even under cohabitation conditions, suggesting that resident microbes are involved in the regulation of Clec4a2. - / - The inhibition of tumor formation in mice was not related to Figure 6G , 6H).
[0405] 3.7 in Clec4a2 - / - In mice, the infiltration of MDSCs and the expression of inflammatory cytokines were reduced, and the expression of Cxcl2 was decreased in polyps.
[0406] Next, real-time RT-PCR and RNA-seq analysis were used to analyze gene expression in polyps and surrounding tissues. - / - In polyp and non-polyp tissues of mice, the expression of Il17a was dramatically reduced compared with that of WT mice ( Figure 7B and 7E). In addition, although the expression of Il17f also decreased, the degree of decrease was smaller than that of Il17a. These expression levels were also confirmed in qPCR ( Figure 7C and 7E ). - / - The mRNA levels of chemokines including Cxcl2 were reduced in polyp and non-polyp tissues of mice ( Fig. 7E ). In addition, RT-PCR also confirmed that the expression of Cxcl2 was reduced ( Fig.7D Consistent with this observation, after AOM-DSS treatment, monocytes expressing CXCR2 (CD11b + Ly6C + ) and granulocytes (CD11b + 6G + )MDSC infiltration into polyps is regulated by Clec4a2 - / - mice were reduced compared with WT mice ( Figure 7F and 7G ). The expression of DCIR (Clec4a2) in polyps was significantly increased compared with the surrounding normal tissues. In addition, the same situation was observed in human colon cancer. In inflammatory bowel disease in humans, the expression was also increased, just like in mice. These results clearly show that DCIR is associated with the occurrence of colitis or intestinal tumors in humans, just like in mice. In addition, it is known that in Clec4a2 - / - In polyp and non-polyp tissues of mice, the expression of Gzmb was reduced compared with that of WT mice ( Fig. 7E ). From these results, we can see that in Clec4a2 - / - In mice, expression of various cytokines and chemokines, including Il17a and Cxcl2, which are important for inducing inflammation, was reduced and associated with reduced recruitment of MDSCs to polyps.
[0407] 3.8 in Clec4a2 - / - In mice, the GM-CSF-Stat5 axis was activated, inhibiting the development of colon cancer.
[0408] In addition, it can be seen that in Clec4a2 - / - In polyp and non-polyp tissues of mice, Csf2 expression was 1000-fold higher than that of WT mice ( Figure 7H ). In addition, in Clec4a2 - / - In mice, the expression of Stat5, a signaling molecule for GM-CSF, also increased significantly ( Fig.7I ). Then, the activation state of the molecule was analyzed. The results showed that Clec4a2 - / - Phosphorylation of Stat5 was increased in polyp and non-polyp tissues of mice ( Figure 7J), after induction of colon tumors, in Clec4a2 - / - In the intestines of mice, the GM-CSF-Stat5 axis is activated.
[0409] 3.9 Anti-NA2 antibodies can inhibit the onset of colitis.
[0410] We found that double-stranded desialylated N-type sugar chain (NA2) is a ligand of DCIR (Kaibu et al.), and immunized galactosyltransferase-1-deficient mice with NA2, which produced antibodies against NA2
[50] . Then, we tested the effect of anti-NA2 antibodies on the onset of DSS-induced colitis. The results showed that the onset of DSS-induced colitis was suppressed in the group given anti-NA2 antibodies compared with the group given isotype Ig. In the group given anti-NA2 antibodies, weight loss was reduced ( Fig. 8A ), the severity of the disease becomes less ( Figure 8B ), the length of the colon increases ( Figure 8C In addition, administration of anti-NA2 antibodies suppressed the expression of Cxcl2, Il17a, and Il6 in the colon, and enhanced the expression of Csf2 ( Fig.8D ). After 4% DSS treatment, Ly6G + Neutrophil infiltration into cLP was significantly reduced compared with the isotype Ig-treated group ( Fig. 8E The occurrence of colonic polyps induced by AOM-DSS was significantly reduced in the anti-NA2 antibody-treated group compared with the Ig-treated group ( Fig.8F These observations suggest that antibodies that inhibit NA2-DCIR interaction could suppress DSS-induced colitis and colon tumorigenesis.
[0411] 4. Investigation
[0412] In this study, the inventors found that the lack of DCIR inhibited the onset of DSS-induced colitis and AOM-DSS-induced colon tumors. - / - In mice, after oral administration of DSS, body weight loss was less, the severity of colitis was milder, and the infiltration of inflammatory cells in the colon was suppressed compared with WT mice. - / - In mice, the development of colon tumors decreased after administration of AOM-DSS. Furthermore, antibodies against NA2, a DCIR ligand, were able to ameliorate colitis and tumor development caused by AOM-DSS. These results suggest that inhibiting DCIR signaling can prevent the development of colitis and colon tumors.
[0413] This suggests that resident microbes play an important role in the pathogenesis of colitis in mice and humans [17, 18]. - / -Mice were co-housed with WT mice to detect Clec4a2 - / - The susceptibility of mice to colitis was also not affected, indicating that the intestinal microbiota is not involved in this phenotype. In addition, tumorigenesis after AOM-DSS treatment was not affected by cohabitation, and the effect of DCIR deficiency on tumorigenesis was not mediated by the microbiota.
[0414] Clec4a2 - / - The finding that mice are resistant to DSS-induced colitis and AOM-DSS-induced tumor formation is in stark contrast to the observation that the onset of autoimmune diseases such as CIA and EAE is exacerbated in these mutant mice [13, 15]. - / - The onset of autoimmune diseases in mice is due to the excessive enhancement of antigen presentation capacity by promoting excessive proliferation and maturation of DCs in this mouse system
[13] . - / - The development of colitis and colon tumors in mice indicated that T cell-mediated autoimmunity dependent on antigen presentation by DCs was not involved in these phenotypes, but rather natural immune responses independent of antigen presentation were involved. - / - In mice, even when DSS-induced colitis was induced, the numbers of Th1, Th2, and Treg cells did not change.
[0415] It can be seen that in Clec4a2 - / - In mice, Csf2 expression increased after DSS treatment compared with WT mice. ILC3 cells are the main GM-CSF-producing cells after DSS treatment [44, 45]. In addition, GM-CSF was expressed in ILC3 cells compared with WT mice after DSS treatment. + The proportion of cells in Clec4a2 - / - The production of GM-CSF by ILC3 is dependent on the production of IL-1β and GM-CSF by macrophages when they perceive microbial signals via TLRs. - / - This altered the effector function of mononuclear phagocytes, reduced the number of Treg cells, and impaired oral tolerance
[45] . Our data suggest that after stimulation with TLR8 and TLR9 agonists or DSS-induced colitis, Clec4a2 - / - Mouse CD11b +In cells, Il1b expression is increased. This is consistent with previous reports that DCIR inhibits the phosphorylation of Erk1 / 2, JNK1 / 2 and p38 in macrophages, thereby inhibiting TLR8 and TLR9-mediated IL-1β production[46-47]. GM-CSF signals are transmitted to myeloid cells through Stat5 phosphorylation
[13] . GM-CSF-Stat5 signaling is essential for the intestinal homeostatic response to intestinal damage. When Stat5 is knocked out in intestinal epithelial cells, NF-κB signaling is increased and the permeability of close junctions is increased
[48] . Mice lacking Stat5 are susceptible to experimental colitis[20,49]. - / - Increased GM-CSF expression in Clec4a2 mice - / - In the colon of mice, phosphorylation of Stat5 was enhanced. This further suggests that rmGM-CSF inhibits the onset of colitis, while anti-GM-CSF worsens colitis. This is consistent with the observations so far: GM-CSF deficiency worsens the onset of colitis, and GM-CSF administration improves colitis in mice [19-21] and humans [22, 23]. From the above results, it can be concluded that excessive production of GM-CSF in the colon does not involve Clec4a2 - / - Suppression of colitis in mice, suggesting that GM-CSF / Stat5 signaling has a protective function in colitis.
[0416] Interestingly, it was found in Clec4a2 - / - In mice, the expression of occludin, Zo1, and claudin, which are junctional complex proteins, increased. Stat5 signaling in the enterocytes protects the enterocytes from impaired close junction barrier function and promotes wound healing of the intestinal mucosa
[48] . The expression of these genes was enhanced by mrGM-CSF treatment and decreased by anti-GM-CSF treatment, indicating that the GM-CSF / Stat5 signaling pathway induces these close junction proteins. Since these proteins are important structural components of close junctions, it is considered that GM-CSF can play an important role in enhancing the barrier function of the intestinal epithelium in addition to promoting the growth and survival of epithelial cells
[23] .
[0417] On the other hand, in Clec4a2 - / -In mice, the expression of inflammatory cytokine genes such as Tnf, Il1, and Il6 was inhibited, indicating that the improvement of colitis was due to the inhibition of the expression of these inflammatory cytokines. In addition, it was shown that the expression of Il1b, Il6, Tnf, and Cxcl2 was inhibited by rmGM-CSF treatment and enhanced by anti-GM-CSF treatment, indicating that the expression of these inflammatory cytokines is controlled by GM-CSF. It is reported that, consistent with the results of the inventors, GM-CSF treatment downregulates the expression of inflammatory cytokines such as Tnf, Il1a, and Il1b
[21] . Furthermore, it can be seen that in Clec4a2 - / - In mice, the expression of Il17a is also significantly suppressed. This is because Stat5, which inhibits the expression of Il17a by competing with Stat3 for binding to the Il17a enhancer, is expressed in Clec4a2. - / - It is overactivated in mice [24, 25].
[0418] The role of IL-17A in the pathogenesis of colitis is controversial. IL-17A is an inflammatory cytokine that plays an important role in the pathogenesis of autoimmune diseases such as EAE and CIA [26, 27]. IL-17A recruits neutrophils and causes inflammation by inducing CXCL2, a chemokine [28, 29].
[0419] Confirmed, in Clec4a2 - / - In mice, the expression of Cxcl2 is reduced, which is coordinated with the decreased expression of Il17a. In IBD, the expression of Il17a is increased
[30] . The expression of CXCL2 is associated with the clinical activity of UC in humans
[31] . It is associated with intestinal mucosal damage in IBD patients, and excessive recruitment and accumulation of activated neutrophils have been observed
[32] . In addition, DSS colitis in mice can be suppressed by blocking CXCR2, which is its receptor [33-35]. These observations suggest that the decreased expression of IL-17A can inhibit Clec4a2 through - / - Neutrophil recruitment in mice helps to alleviate colitis. However, treatment with anti-IL-17A neutralizing antibodies has been reported to be ineffective and may even worsen the condition of IBD patients
[36] . In addition, in experimental colitis models, Il17a - / - The onset of colitis in mice was also aggravated, and Il17f was resistant to induced colitis. - / - Mouse control
[0420] [37-39]. These observations suggest that IL-17A may play a protective role against the onset of colitis. Consistent with this view, IL-17A has been reported to play an important role in maintaining the barrier integrity of the intestinal epithelium by controlling the intracellular localization of the close-binding protein occludin in colonic epithelial cells
[40] . - / - Reduced expression of IL-17A in mice was associated with suppression of colitis in these mice, but was not considered to be the primary cause.
[0421] The results show that in Clec4a2 - / - In mice, the development of colon tumors induced by AOM-DSS was also suppressed, as was the development of DSS-induced colitis. Compared with WT mice, the expression of Csf2 was greatly increased in both polyp and non-polyp areas in mutant mice. - / - In mice, similar to mice with DSS-induced colitis, the expression of Il17a, Il1b, Tnf, and Cxcl2 was reduced. Since inflammation promotes tumor formation, if Clec4a2 - / - Increased inflammation in the intestine of mice may promote tumor formation. From this point of view, IL-17A promotes tumor formation through angiogenesis
[41] . In addition, IL-1 also promotes tumor formation
[42] . CXCR2 deficiency can significantly inhibit tumor formation associated with chronic inflammation and colitis of the colon by inhibiting the infiltration of MDSC into the colon mucosa and tumors[34,43]. Therefore, it is believed that inhibition of Clec4a2 - / - The development of tumors induced by AOM-DSS in mice was attributed to the reduction of inflammatory cytokine production and MDSC infiltration.
[0422] This suggests that we can inhibit DSS-induced colitis and AOM-DSS-induced tumor formation by inhibiting the interaction between DCIR and its ligand NA2 using anti-NA2 antibodies. After anti-NA2 treatment, the expression of Csf2 increased, and the expression of Il17a, Il6, Il1b, and Cxcl2 decreased, which is consistent with the expression of Clec4a2. - / -The results are consistent with those observed in mice. These results show that the NA2-DCIR axis plays an important role in controlling the immune response induced by natural immune receptors such as TLR8 and TLR9 in the intestine. Under physiological conditions, DCIR controls the excessive differentiation and activation of DC to prevent autoimmunity. However, since the DCIR signal controls the natural immune signal in the intestine and inhibits the induction of GM-CSF, the intestine becomes vulnerable to the production of inflammation and tumors. Therefore, by hindering the activation of DCIR, it is possible to inhibit the production of intestinal inflammation and tumors via the natural immune mechanism. In addition, since NA2 has the same structure in humans and mice, it is believed that the above findings can be applied to humans. These findings are considered to be clues for the development of new treatments for colitis and colon tumors.
[0423] <Example 2>
[0424] 1. Introduction
[0425] Anti-DCIR antibodies inhibit the binding of NA2 and DCIR and can be used to treat inflammatory bowel disease and intestinal tumors. Therefore, anti-DCIR antibodies were prepared and their binding properties to DCIR and their ability to inhibit NA2-DCIR binding were evaluated.
[0426] 2. Materials and Methods
[0427] 2.1 Preparation of anti-DCIR antibody
[0428] Anti-DCIR antibodies were established using the following process. DCIR-expressing cell lines were mixed with an immune adjuvant (Titer Max), DCIR-deficient mice were immunized twice, and the mice were euthanized. Spleen cells were collected and fused with diffuse cells to produce hybridoma cells, and a monoclonal library caused by limiting dilution was produced. Next, DCIR-specific antibodies were identified based on their binding activity to DCIR-expressing cells and DCIR proteins. The established monoclonal antibody-producing hybridomas were acclimated to serum-free culture medium, and finally, the antibodies were purified from the cell culture medium using Protein-L-bound beads.
[0429] RNA was purified from the monoclonal antibody-producing hybridoma cells, cDNA was prepared, and DNA sequence analysis from FR1 to FR4 was performed. The base sequence and amino acid sequence of the prepared anti-DCIR antagonist antibody are shown in Fig.14A and Fig. 14B .
[0430] 2.2 Binding of anti-DCIR antibodies to mouse and human DCIR
[0431] Anti-DCIR antibody or isotype antibody (10 μg / ml) was added to the bottom of a 96-well plate and allowed to stand overnight at 4°C to bind to the plate. The plate was blocked with PBS containing 10% (w / v) FCS, and Fc or mouse DCIR-Fc or human DCIR-Fc (5 μg / ml) was added. The plate was allowed to stand for 1 hour at room temperature, and after washing, the plate-bound Fc mouse DCIR-Fc or human DCIR-Fc (5 μg / ml) was detected using Peroxidase-conjugated anti-human Fc (Jackson Immunoresearch). Fig.11 ).
[0432] 2.3 Inhibition of the binding between NA2-expressing cells (Lec2) and DCIR by anti-DCIR antibodies
[0433] DCIR-Fc and isotype antibody (5 μg / ml) or anti-DCIR antibody (0 μg / ml, 1 μg / ml, 10 μg / ml) were added to Lec2 cells expressing NA2, suspended, and allowed to stand on ice for 30 minutes. The cells were washed, and the binding of DCIR-Fc protein to Lec2 cells was detected using fluorescently labeled anti-human Fc antibody.
[0434] 3. Results and Investigation
[0435] The anti-DCIR antibody produced showed binding activity to mouse and human DCIR ( Fig.12 In addition, it was confirmed that the prepared anti-DCIR antibody has the ability to inhibit the binding between NA2-expressing cells (Lec2) and DCIR ( Fig.13 ). The antibody was shown to bind to human DCIR antibody and inhibit the binding of DCIR to NA2, indicating that the antibody may be effectively used in new drugs.
[0436] <Example 3>
[0437] Confirmation of antagonist activity of anti-DCIR antibodies
[0438] Myeloid cells from wild-type or DCIR-deficient mice were cultured in M-CSF (20 ng / mL) for 2 days, and then cultured with M-CSF (20 ng / mL) and RANKL (100 ng / mL) for 4 days. Isotype or recombinant anti-DCIR antagonist antibody (5A3D8_recombinant) was added at 1 μg / mL at the beginning of culture and when the culture medium was replaced. After TRAP staining, TRAP-positive cells with a cell diameter of 100 to 200 μm and multinucleated cells larger than 200 μm were counted as osteoclasts. The graph shows the mean and standard deviation of the number of osteoclasts in 4 replicate wells, and the test was performed by student's t-test. *; p < 0.05, iso VS anti-DCIR antibody. The data of an experiment performed once are shown ( Fig.15A , B).
[0439] As a result, the anti-DCIR antibody promoted osteoclast differentiation. In contrast to the anti-DCIR agonist antibody, the anti-DCIR agonist antibody promoted osteoclast differentiation, indicating that the antibody is not an agonist but an antagonist antibody.
[0440] References
[0441] 1.Maloy KJ,Powrie F.Intestinal homeostasis and its breakdown ininflammatory bowel disease.Nature 474,298-306(2011).
[0442] 2. Kmiec Z, Cyman M, Slebioda TJ. Cells of the innate and adaptive immunity and their interactions in inflammatory bowel disease. Adv Med Sci. 62, 1-16 (2017).
[0443] 3. Borregaard N. Neutrophils, from marrow to microbes. Immunity 33, 657-670 (2010).
[0444] 4.Tang C et al. Myeloid C-type lectin receptors in skin / mucoepithelialdiseases and tumors. J Leukoc Biol. 106,903-917(2019).
[0445] 5.Shinobu Saijo et al.Dectin-1is required for host defense againstPneumocystis carinii but not against Candida albicans.Nat Immunol.8,39-46(2007).
[0446] 6.Ce Tang et al.Inhibition of Dectin-1 Signaling Ameliorates Colitisby Inducing Lactobacillus-Mediated Regulatory T Cell Expansion in theIntestine.Cell Host&Microbe 18,183-197(2015).
[0447] 7.Saba K et al.A C-type lectin MGL1 / CD301a plays an anti-inflammatoryrole in murine experimental colitis.Am J Pathol.174,144-152(2009).
[0448] 8.Huang,X.et al.Cloning and characterization of a novelITIMcontaining lectin-like immunoreceptor LLIR and its two transmembraneregiondeletion variants.Biochem.Biophys.Res.Commun.281,131-140(2001).
[0449] 9.Kanazawa,N.et al.DCIR acts as an inhibitory receptor dependingonits.immunoreceptor tyrosine-based inhibitory motif.J.Invest.Dermatol.118,261-266(2002).
[0450] 10.Bates,E.E.et al.APCs express DCIR,a novel C-type lectinsurfacereceptor containing an immunoreceptor tyrosine-based inhibitorymotif.J.Immunol.163,1973-1983(1999).
[0451] 11.Kaifu T et al.Dendritic Cell Immunoreceptor(DCIR):AnITIM-HarboringC-Type Lectin Receptor.C-Type Lectin Receptors inImmunity.103-113(2016).
[0452] 12.Daigle,I.et al.Death receptors bind SHP-1 and blockcytokine-induced anti-apoptotic signaling in neutrophils.Nat.Med.8,61-67(2002).
[0453] 13.Fujikado N et al.D et al.Dcir deficiency causes developmentofautoimmune diseases in mice due to excess expansion of dendriticcells.Nat.Med.14,176-180(2008).
[0454] 14.Maruhashi T.et al.DCIR Maintains Bone Homeostasis byRegulatingIFN-g Production in T Cells.J.Immunol.194,5681-5691(2015).
[0455] 15.Akimasa Seno et al.Exacerbation of experimentalautoimmuneencephalomyelitis in mice deficient for DCIR,an inhibitory C-typelectinreceptor.Exp.Anim.64,109-119(2015).
[0456] 16.M.Dougan et al.GM-CSF,IL-3,and IL-5 family of cytokines:Regulatorsof inflammation.Immunity 50,796-811(2019).
[0457] 17.Mayne CG et al.Induced and natural regulatory T cells inthedevelopment of inflammatory bowel disease.Inflamm Bowel Dis.19,1772-1788(2013).
[0458] 18.Maul J et al.Peripheral and intestinal regulatory CD4+CD25(high)Tcells in inflammatory bowel disease.Gastroenterology 128,1868-1878(2005)
[0459] 19.Xu Y et al.The role of granulocyte macrophage-colonystimulatingfactor in acute intestinal inflammation.Cell Res.18,1220-1229(2008).
[0460] 20.Han et al.Loss of GM-CSF signalling in non-haematopoieticcellsincreases NSAID ileal injury.Gut 59,1066-1078(2010).
[0461] 21.Sainathan SK et al.Granulocyte macrophage colony-stimulatingfactorameliorates DSS induced experimental colitis.Inflamm Bowel Dis.14,88-99(2008).
[0462] 22.J.R.Korzenik et al.Sargramostim in Crohn’s Disease Study Group,Sargramostim for active Crohn’s disease.N.Engl.J.Med.352,2193-22-1(2005).
[0463] 23.Daebritz J et al.Granulocyte macrophage colony-stimulatingfactorand the intestinal innate immune cell homeostasis in Crohn’s disease.AmJPhysiol Gstrointest Liver Physiol.306,455-465(2014).
[0464] 24.Yang et al.Opposing regulation of the locus encoding IL-17throughdirect,reciprocal actions of STAT3 and STAT5.Nature immunology 12,247-254(2011).
[0465] 25.Arian Laurence et al.Interleukin-2 Signaling via STAT5 ConstrainsTHelper 17 Cell Generation.Immunity.26,371-381(2007).
[0466] 26.Komiyama Y et al.IL-17 Plays an Important Role in theDevelopmentof Experimental Autoimmune Encephalomyelitis.J Immunol.177,566-573(2006).
[0467] 27.Nakae S et al.IL-17 production from activated T cells is requiredforthe spontaneous development of destructive arthritis in mice deficient inIL-1receptor antagonist.PNAS.100,5986-5990(2003).
[0468] 28.Iwakura Y et al.Functional specialization of interleukin-17familymembers.Immunity 34,149-162(2011).
[0469] 29.Ye P et al.Requirement of interleukin 17 receptor signaling forlungCXC chemokine and granulocyte colony-stimulating factor expression,neutrophil recruitment,and host defense.J.Exp.Med.194,519-527(2001).
[0470] 30.Fujino S et al.Increased expression of interleukin 17 ininflammatorybowel disease.Gut 52,65-70(2013).
[0471] 31.Paulo et al.Conserved transcriptomic profile between mouseandhuman colitis allows unsupervised patient stratification.NatureCommunications 10,2892(2019).
[0472] 32.Mieke et al.Neutrophil chemoattractant receptors in healthanddisease:double-edged swords.Cellular&Molecular Immunology 17,433-450(2020).
[0473] 33.Buanne P et al.Crucial pathophysiological role of CXCR2inexperimental ulcerative colitis in mice.J Leukoc Biol.85,1239-1246(2007).
[0474] 34.Fournier BM et al.The role of neutrophils duringintestinalinflammation.Mucosal Immunol.5,354-366(2012).
[0475] 35.Koji et al.Microbiome-mediated neutrophil recruitment via CXCR2andprotection from amebic colitis.Plos Pathogens 13,e1006513(2017).
[0476] 36.Hueber W et al.Secukinumab,a human anti-IL-17A monoclonalantibody,for moderate to severe Crohn's disease:unexpected results of arandomised,double-blind placebo-controlled trial.,Secukinumab in Crohn'sDisease StudyGroup.Gut 61,1693-1700(2012).
[0477] 37.Tang C et al.Suppression of IL-17F,but not of IL-17A,providesprotection against colitis by inducing T reg cells throughmodification of theintestinal microbiota.Nat.Immunol.19,755-765(2018).
[0478] 38.O’Connor W et al.A protective function for interleukin 17A inTcell-mediated intestinal inflammation.Nat Immunol.10,603-609 2009.
[0479] 39.Yang et al.Regulation of inflammatory responses by IL-17F.JExpMed.205,1063-1075(2008).
[0480] 40.Lee et al.Interleukin-23-Independent IL-17 ProductionRegulatesIntestinal Epithelial Permeability.Immunity 43,727-738(2015).
[0481] 41.Zhao et al.The role of interleukin-17 in tumor developmentandprogression.J Exp Med.217,e20190297(2020).
[0482] 42.Krelin et al.Interleukin-1β-Driven Inflammation Promotes theDevelopment and Invasiveness of Chemical Carcinogen-Induced Tumors.CancerRes.67,1062-1071(2007).
[0483] 43.H.Katoh et al.CXCR2-expressing myeloid-derived suppressor cellsare essential to promote colitis-associated tumorigenesis.Cancer Cell 24,631-644(2013).
[0484] 44.Tomas C.D et al.GM-CSF Calibrates Macrophage Defense and WoundHealing Programs during Intestinal Infection and Inflammation.Cell Report.32,107857(2020).
[0485] 45.Arthur M.et al.Microbiota-Dependent Crosstalk Between Macrophagesand ILC3 Promotes Intestinal Homeostasis.Science 343,1249288(2014).
[0486] 46.Zhao et al.DCIR negatively regulates CpG-ODN-induced IL-1βand IL-6production.Mol Immunol.68,641-647(2015).
[0487] 47. Meyer-Wentrup, F. et al. DCIR is endocytosed into human dendritic cells and inhibits TLR8-mediated cytokine production. J. Leukoc. Biol. 85, 518-525 (2009).
[0488] 48. Shila G. et al. Enterocyte STAT5 promotes mucosal wound healing via suppression of myosin light chain kinase-mediated loss of barrier function and inflammation. EMBO Mol Med. 4, 109-124 (2011).
[0489] 49.Han et al.Signal Transducer and Activator of Transcription5bPromotes Mucosal Tolerance in Pediatric Crohn's Disease and MurineColitis.Am J Pathol.169,1999-2013(2006).
[0490] 50. Kaifu, T.*, Yabe, R.*, Maruhashi, T.*, Chung, S.-H.*, Tateno, H., Fujikado, N., Hirabayashi, J., and Iwakura, Y. DCIR and its ligand asialo-biantennary N-glycan regulate DC function and osteoclastogenesis.J.Exp.Med.,218,e20210435(2021).
[0491] The disclosure of Japanese Patent Application No. 2022-008129 is incorporated herein by reference in its entirety. All documents, patent applications, and technical specifications described in this specification are incorporated herein by reference to the same extent as if each document, patent application, and technical specification were specifically and individually described as being incorporated by reference.
Claims
1. A pharmaceutical composition for treating or preventing at least one disease selected from the group consisting of inflammatory bowel disease and intestinal tumors, the pharmaceutical composition comprising: a dendritic cell immunoreceptor-double-stranded desialylated N-type sugar chain binding inhibitor, or a dendritic cell immunoreceptor inhibitor; and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition according to claim 1, wherein The dendritic cell immunoreceptor-double-stranded desialylated N-type sugar chain binding inhibitor or the dendritic cell immunoreceptor inhibitor is an antibody.
3. The pharmaceutical composition according to claim 1 or 2, wherein The binding inhibitor between dendritic cell immune receptor and double-chain desialylated N-type sugar chain is an anti-double-chain desialylated N-type sugar chain antibody.
4. The pharmaceutical composition according to claim 1 or 2, wherein The dendritic cell immunoreceptor-double-stranded desialylated N-type sugar chain binding inhibitor or the dendritic cell immunoreceptor inhibitor is an anti-dendritic cell immunoreceptor antibody.
5. The pharmaceutical composition according to claim 2, wherein The antibody is a mouse antibody, a chimeric antibody, a humanized antibody, or a human antibody.
6. The pharmaceutical composition according to claim 2, wherein The antibody is a humanized antibody.
7. The pharmaceutical composition according to claim 2, wherein The antibody is a full-length antibody or a low-molecular-weight antibody selected from the group consisting of Fab, Fab', F(ab')2, scFv, and bispecific antibodies.
8. The pharmaceutical composition according to any one of claims 1 to 7, wherein The intestinal tumor includes at least one selected from the group consisting of colon cancer, rectal cancer, and small intestine cancer.
9. The pharmaceutical composition according to any one of claims 1 to 8, wherein The inflammatory bowel disease comprises at least one selected from the group consisting of Crohn's disease and ulcerative colitis.
